Paolo Corradini

Paolo Corradini's AcademicInfluence.com Rankings

Paolo Corradini

Medical

#3197

World Rank

#3652

Historical Rank

Hematology

#49

World Rank

#55

Historical Rank

Surgery

#269

World Rank

#328

Historical Rank

medical Degrees

Paolo Corradini

Philosophy

#9181

World Rank

#12701

Historical Rank

Logic

#6170

World Rank

#7658

Historical Rank

philosophy Degrees

Download Badge

Medical
Philosophy

Paolo Corradini's Degrees

Doctorate Medicine University of Bologna
PhD Hematology University of Bologna

Why Is Paolo Corradini Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Paolo Corradini's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study (2010) (790)
Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial. (2014) (703)
Autologous transplantation and maintenance therapy in multiple myeloma. (2014) (642)
Indications for allogeneic stem cell transplantation in chronic lymphocytic leukemia: the EBMT transplant consensus (2007) (423)
Deregulation of MUM1/IRF4 by chromosomal translocation in multiple myeloma (1997) (372)
Allogeneic stem cell transplantation after reduced-intensity conditioning in patients with myelofibrosis: a prospective, multicenter study of the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. (2009) (344)
Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study (2020) (339)
Melphalan, prednisone, and lenalidomide treatment for newly diagnosed myeloma: a report from the GIMEMA--Italian Multiple Myeloma Network. (2007) (318)
B cell lymphoma-associated chromosomal translocation involves candidate oncogene lyt-10, homologous to NF-κB p50 (1991) (316)
Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study (2019) (316)
Rearrangements of the BCL6 gene in diffuse large cell non-Hodgkin's lymphoma. (1994) (303)
Graft-versus-lymphoma effect in relapsed peripheral T-cell non-Hodgkin's lymphomas after reduced-intensity conditioning followed by allogeneic transplantation of hematopoietic cells. (2004) (302)
Chromosomal translocations cause deregulated BCL6 expression by promoter substitution in B cell lymphoma. (1995) (288)
Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial. (2015) (278)
Aspirin or enoxaparin thromboprophylaxis for patients with newly diagnosed multiple myeloma treated with lenalidomide. (2012) (266)
Allogeneic hematopoietic stem cell transplantation for chronic myeloid leukemia in Europe 2006: transplant activity, long-term data and current results. An analysis by the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). (2006) (262)
Molecular and clinical remissions in multiple myeloma: role of autologous and allogeneic transplantation of hematopoietic cells. (1999) (247)
Long-term follow-up of patients with peripheral T-cell lymphomas treated up-front with high-dose chemotherapy followed by autologous stem cell transplantation (2006) (243)
Prospective, multicenter randomized GITMO/IIL trial comparing intensive (R-HDS) versus conventional (CHOP-R) chemoimmunotherapy in high-risk follicular lymphoma at diagnosis: the superior disease control of R-HDS does not translate into an overall survival advantage. (2008) (243)
Eradication of polymerase chain reaction-detectable chronic lymphocytic leukemia cells is associated with improved outcome after bone marrow transplantation. (1996) (222)
Long-term remission in mantle cell lymphoma following high-dose sequential chemotherapy and in vivo rituximab-purged stem cell autografting (R-HDS regimen). (2003) (219)
Nonmyeloablative conditioning followed by hematopoietic cell allografting and donor lymphocyte infusions for patients with metastatic renal and breast cancer. (2002) (210)
Daratumumab plus bortezomib and dexamethasone versus bortezomib and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of CASTOR (2018) (202)
Managing high-risk CLL during transition to a new treatment era: stem cell transplantation or novel agents? (2014) (195)
Treatment-related mortality and graft-versus-leukemia activity after allogeneic stem cell transplantation for chronic lymphocytic leukemia using intensity-reduced conditioning (2003) (193)
Molecular remission after myeloablative allogeneic stem cell transplantation predicts a better relapse-free survival in patients with multiple myeloma. (2003) (185)
Bortezomib as induction before autologous transplantation, followed by lenalidomide as consolidation-maintenance in untreated multiple myeloma patients. (2010) (177)
Autologous/reduced-intensity allogeneic stem cell transplantation vs autologous transplantation in multiple myeloma: long-term results of the EBMT-NMAM2000 study. (2013) (171)
Antitumor effects of HSV-TK-engineered donor lymphocytes after allogeneic stem-cell transplantation. (2007) (171)
Tandem autologous/reduced-intensity conditioning allogeneic stem-cell transplantation versus autologous transplantation in myeloma: long-term follow-up. (2011) (171)
Molecular monitoring of minimal residual disease in follicular and mantle cell non-Hodgkin's lymphomas treated with high-dose chemotherapy and peripheral blood progenitor cell autografting. (1997) (170)
Reduced-intensity conditioning lowers treatment-related mortality of allogeneic stem cell transplantation for chronic lymphocytic leukemia: a population-matched analysis (2005) (162)
High-dose sequential chemoradiotherapy in multiple myeloma: residual tumor cells are detectable in bone marrow and peripheral blood cell harvests and after autografting. (1995) (160)
Allogeneic transplantation improves the overall and progression-free survival of Hodgkin lymphoma patients relapsing after autologous transplantation: a retrospective study based on the time of HLA typing and donor availability. (2008) (159)
Reduced-intensity conditioning followed by allografting of hematopoietic cells can produce clinical and molecular remissions in patients with poor-risk hematologic malignancies. (2002) (156)
Genomic landscape and chronological reconstruction of driver events in multiple myeloma (2018) (153)
Risk factors for the development of secondary malignancy after high-dose chemotherapy and autograft, with or without rituximab: a 20-year retrospective follow-up study in patients with lymphoma. (2011) (148)
Antibiotic prophylaxis before dental procedures may reduce the incidence of osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates (2008) (148)
Peripheral T-cell lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2015) (147)
Early Chemotherapy Intensification With Escalated BEACOPP in Patients With Advanced-Stage Hodgkin Lymphoma With a Positive Interim Positron Emission Tomography/Computed Tomography Scan After Two ABVD Cycles: Long-Term Results of the GITIL/FIL HD 0607 Trial. (2018) (141)
Allogeneic stem cell transplantation following reduced-intensity conditioning can induce durable clinical and molecular remissions in relapsed lymphomas: pre-transplant disease status and histotype heavily influence outcome (2007) (139)
Safety and efficacy of pomalidomide plus low-dose dexamethasone in STRATUS (MM-010): a phase 3b study in refractory multiple myeloma. (2016) (138)
Mutational activation of N- and K-ras oncogenes in plasma cell dyscrasias. (1993) (136)
Genomic patterns of progression in smoldering multiple myeloma (2018) (135)
Thalidomide downregulates angiogenic genes in bone marrow endothelial cells of patients with active multiple myeloma. (2005) (133)
Busulfan plus cyclophosphamide versus busulfan plus fludarabine as a preparative regimen for allogeneic haemopoietic stem-cell transplantation in patients with acute myeloid leukaemia: an open-label, multicentre, randomised, phase 3 trial. (2015) (133)
Continuous Therapy Versus Fixed Duration of Therapy in Patients With Newly Diagnosed Multiple Myeloma. (2015) (132)
Allogeneic hematopoietic stem cell transplantation with reduced-intensity conditioning in acute lymphoblastic leukemia: a feasibility study. (2003) (131)
A prospective, international phase 2 study of bortezomib retreatment in patients with relapsed multiple myeloma (2013) (128)
Infliximab treatment for steroid-refractory acute graft-versus-host disease. (2004) (127)
COVID-19 infection in adult patients with hematological malignancies: a European Hematology Association Survey (EPICOVIDEHA) (2021) (126)
Long-term follow-up of indolent lymphoma patients treated with high-dose sequential chemotherapy and autografting: evidence that durable molecular and clinical remission frequently can be attained only in follicular subtypes. (2004) (126)
Allogeneic transplantation following a reduced-intensity conditioning regimen in relapsed/refractory peripheral T-cell lymphomas: long-term remissions and response to donor lymphocyte infusions support the role of a graft-versus-lymphoma effect (2012) (122)
Role of naive-derived T memory stem cells in T-cell reconstitution following allogeneic transplantation. (2015) (121)
Evidence for a bone marrow B cell transcribing malignant plasma cell VDJ joined to C mu sequence in immunoglobulin (IgG)- and IgA-secreting multiple myelomas (1993) (120)
Inactivation of tumor suppressor genes, p53 and Rb1, in plasma cell dyscrasias. (1994) (116)
High-dose therapy and autologous stem-cell transplantation in Waldenstrom macroglobulinemia: the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. (2010) (115)
A novel nested-PCR strategy for the detection of rearranged immunoglobulin heavy-chain genes in B cell tumors (1997) (113)
Post-Transplantation Cyclophosphamide-Based Haploidentical Transplantation as Alternative to Matched Sibling or Unrelated Donor Transplantation for Hodgkin Lymphoma: A Registry Study of the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation. (2017) (110)
The hematopoietic cell transplantation comorbidity index (HCT-CI) predicts clinical outcomes in lymphoma and myeloma patients after reduced-intensity or non-myeloablative allogeneic stem cell transplantation (2009) (108)
Primary Analysis of Juliet: A Global, Pivotal, Phase 2 Trial of CTL019 in Adult Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (2017) (105)
Detection of immunoglobulin gene rearrangement of B cell non-Hodgkin's lymphomas and leukemias in fresh, unfixed and formalin-fixed, paraffin-embedded tissue by polymerase chain reaction. (1993) (101)
High rate of clinical and molecular remissions in follicular lymphoma patients receiving high-dose sequential chemotherapy and autografting at diagnosis: a multicenter, prospective study by the Gruppo Italiano Trapianto Midollo Osseo (GITMO). (2002) (100)
Nonmyeloablative allografting for newly diagnosed multiple myeloma: the experience of the Gruppo Italiano Trapianti di Midollo. (2009) (100)
Prognostic factors for donor lymphocyte infusions following non-myeloablative allogeneic stem cell transplantation in multiple myeloma (2006) (97)
Indications for hematopoietic stem cell transplantation in patients with follicular lymphoma: a consensus project of the EBMT-Lymphoma Working Party (2013) (96)
Analysis of the genomic landscape of multiple myeloma highlights novel prognostic markers and disease subgroups (2017) (94)
Pharmacologic Inhibition of JAK1/JAK2 Signaling Reduces Experimental Murine Acute GVHD While Preserving GVT Effects (2015) (92)
B cell lymphoma-associated chromosomal translocation involves candidate oncogene lyt-10, homologous to NF-kappa B p50. (1991) (92)
Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): a multicentre, open-label, single-arm, phase 2 study. (2021) (91)
Long-term outcome and prospective validation of NIH response criteria in 39 patients receiving imatinib for steroid-refractory chronic GVHD. (2013) (89)
Post-transplant immunotherapy with donor-lymphocyte infusion and novel agents to upgrade partial into complete and molecular remission in allografted patients with multiple myeloma. (2009) (89)
Pomalidomide, cyclophosphamide, and prednisone for relapsed/refractory multiple myeloma: a multicenter phase 1/2 open-label study. (2013) (87)
Incidence, Risk Factors and Outcome of Pre-engraftment Gram-Negative Bacteremia After Allogeneic and Autologous Hematopoietic Stem Cell Transplantation: An Italian Prospective Multicenter Survey (2017) (87)
Increased basal and thrombin-induced free calcium in platelets of essential hypertensive patients. (1987) (85)
Remarkable activity of novel agents bortezomib and thalidomide in patients not responding to donor lymphocyte infusions following nonmyeloablative allogeneic stem cell transplantation in multiple myeloma. (2006) (83)
Management of multiple myeloma and related-disorders: guidelines from the Italian Society of Hematology (SIE), Italian Society of Experimental Hematology (SIES) and Italian Group for Bone Marrow Transplantation (GITMO). (2004) (82)
Prolonged survival in poor-risk diffuse large B-cell lymphoma following front-line treatment with rituximab-supplemented, early-intensified chemotherapy with multiple autologous hematopoietic stem cell support: a multicenter study by GITIL (Gruppo Italiano Terapie Innovative nei Linfomi) (2007) (78)
Bortezomib induction, reduced-intensity transplantation, and lenalidomide consolidation-maintenance for myeloma: updated results. (2013) (77)
Timing the initiation of multiple myeloma (2019) (76)
Intensified chemo-immunotherapy with or without stem cell transplantation in newly diagnosed patients with peripheral T-cell lymphoma (2014) (75)
Brentuximab vedotin in relapsed/refractory Hodgkin’s lymphoma: the Italian experience and results of its use in daily clinical practice outside clinical trials (2013) (75)
Maspin and mammaglobin genes are specific markers for RT-PCR detection of minimal residual disease in patients with breast cancer. (2001) (74)
PTCy-based haploidentical vs matched related or unrelated donor reduced-intensity conditioning transplant for DLBCL. (2019) (73)
Allogeneic stem cell transplantation in multiple myeloma relapsed after autograft: a multicenter retrospective study based on donor availability. (2012) (73)
The impact of donor gender on outcome of allogeneic hematopoietic stem cell transplantation for multiple myeloma: reduced relapse risk in female to male transplants (2005) (72)
Inactivated varicella zoster vaccine in autologous haemopoietic stem-cell transplant recipients: an international, multicentre, randomised, double-blind, placebo-controlled trial (2018) (71)
G-CSF administration following peripheral blood progenitor cell (PBPC) autograft in lymphoid malignancies: evidence for clinical benefits and reduction of treatment costs (1998) (70)
A validated real-time quantitative PCR approach shows a correlation between tumor burden and successful ex vivo purging in follicular lymphoma patients. (2001) (70)
Endobronchial metastasis: an epidemiologic and clinicopathologic study of 174 consecutive cases. (2014) (69)
Biological and prognostic impact of APOBEC-induced mutations in the spectrum of plasma cell dyscrasias and multiple myeloma cell lines (2017) (68)
Rituximab improves the efficacy of high-dose chemotherapy with autograft for high-risk follicular and diffuse large B-cell lymphoma: a multicenter Gruppo Italiano Terapie Innnovative nei linfomi survey. (2008) (67)
Phase IA/II, multicentre, open‐label study of the CD40 antagonistic monoclonal antibody lucatumumab in adult patients with advanced non‐Hodgkin or Hodgkin lymphoma (2014) (67)
The EBMT/EMCL consensus project on the role of autologous and allogeneic stem cell transplantation in mantle cell lymphoma (2014) (65)
Haploidentical stem cell transplantation after a reduced-intensity conditioning regimen for the treatment of advanced hematologic malignancies: posttransplantation CD8-depleted donor lymphocyte infusions contribute to improve T-cell recovery. (2009) (65)
Key concepts and critical issues on epoetin and filgrastim biosimilars. A position paper from the Italian Society of Hematology, Italian Society of Experimental Hematology, and Italian Group for Bone Marrow Transplantation (2011) (65)
Qualitative and quantitative polymerase chain reaction monitoring of minimal residual disease in relapsed chronic lymphocytic leukemia: early assessment can predict long-term outcome after reduced intensity allogeneic transplantation (2009) (62)
T‐cell immune response after mRNA SARS‐CoV‐2 vaccines is frequently detected also in the absence of seroconversion in patients with lymphoid malignancies (2021) (62)
Overweight as an adverse prognostic factor for non-Hodgkin's lymphoma patients receiving high-dose chemotherapy and autograft (2000) (62)
Graft monocytic myeloid-derived suppressor cell content predicts the risk of acute graft-versus-host disease after allogeneic transplantation of granulocyte colony-stimulating factor-mobilized peripheral blood stem cells. (2014) (60)
Use of recombinant human growth hormone (rhGH) plus recombinant human granulocyte colony-stimulating factor (rhG-CSF) for the mobilization and collection of CD34+ cells in poor mobilizers. (2004) (60)
Daratumumab, Bortezomib, and Dexamethasone Versus Bortezomib and Dexamethasone in Patients With Previously Treated Multiple Myeloma: Three-year Follow-up of CASTOR. (2019) (58)
Randomized Trial Comparing R-CHOP Versus High-Dose Sequential Chemotherapy in High-Risk Patients With Diffuse Large B-Cell Lymphomas. (2016) (57)
Advances in mobilization for the optimization of autologous stem cell transplantation (2009) (57)
Effect of age and previous autologous transplantation on nonrelapse mortality and survival in patients treated with reduced-intensity conditioning and allografting for advanced hematologic malignancies. (2005) (57)
Practical management of ibrutinib in the real life: Focus on atrial fibrillation and bleeding (2018) (53)
Prognostic factors for survival in patients with advanced renal cell carcinoma undergoing nonmyeloablative allogeneic stem cell transplantation (2005) (51)
Detection of circulating tumor cells in multiple myeloma by a PCR-based method. (1993) (51)
Concurrent administration of high-dose chemotherapy and rituximab is a feasible and effective chemo/immunotherapy for patients with high-risk non-Hodgkin's lymphoma (2001) (51)
Allogeneic transplantation of unmanipulated peripheral blood stem cells in patients with multiple myeloma (1998) (50)
Long-term follow-up of advanced-stage low-grade lymphoma patients treated upfront with high-dose sequential chemotherapy and autograft (2000) (46)
Bortezomib with or without dexamethasone in relapsed multiple myeloma following allogeneic hematopoietic cell transplantation. (2006) (46)
COVID‐19 elicits an impaired antibody response against SARS‐CoV‐2 in patients with haematological malignancies (2021) (45)
COVID-19 in vaccinated adult patients with hematological malignancies: preliminary results from EPICOVIDEHA (2021) (45)
Engraftment capacity of mesenchymal cells following hematopoietic stem cell transplantation in patients receiving reduced-intensity conditioning regimen (2006) (44)
High XBP1 expression is a marker of better outcome in multiple myeloma patients treated with bortezomib (2014) (44)
No improvement of survival with reduced- versus high-intensity conditioning for allogeneic stem cell transplants in Ewing tumor patients. (2011) (42)
PCR-detectable nonneoplastic Bcl-2/IgH rearrangements are common in normal subjects and cancer patients at diagnosis but rare in subjects treated with chemotherapy. (2003) (42)
Oral Revlimid® Plus Melphalan and Prednisone (R-MP) for Newly Diagnosed Multiple Myeloma: Results of a Multicenter Phase I/II Study. (2006) (41)
Clinical relevance of minimal residual disease monitoring in non-Hodgkin’s lymphomas: a critical reappraisal of molecular strategies (1999) (41)
The role of positron emission tomography with 18F-fluorodeoxyglucose integrated with computed tomography in the evaluation of patients with multiple myeloma undergoing allogeneic stem cell transplantation. (2015) (40)
Efficacy of Daratumumab, Bortezomib, and Dexamethasone Versus Bortezomib and Dexamethasone in Relapsed or Refractory Myeloma Based on Prior Lines of Therapy: Updated Analysis of Castor (2016) (40)
Negative immunomagnetic ex vivo purging combined with high-dose chemotherapy with peripheral blood progenitor cell autograft in follicular lymphoma patients: evidence for long-term clinical and molecular remissions (1999) (39)
Rapid generation of antiplasma cell activity in the bone marrow of myeloma patients by CD3-activated T cells. (1993) (39)
Impact of cytomegalovirus replication and cytomegalovirus serostatus on the outcome of patients with B cell lymphoma after allogeneic stem cell transplantation. (2014) (39)
Post-transplant cyclophosphamide-based haplo-identical transplantation as alternative to matched sibling or unrelated donor transplantation for non-Hodgkin lymphoma: a registry study by the European society for blood and marrow transplantation (2016) (39)
Reduced-intensity conditioning containing low-dose alemtuzumab before allogeneic peripheral blood stem cell transplantation: graft-versus-host disease is decreased but T-cell reconstitution is delayed. (2005) (39)
Myeloablative versus reduced intensity allogeneic stem cell transplantation for relapsed/refractory Hodgkin's lymphoma in recent years: a retrospective analysis of the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. (2016) (38)
Phase II study of sorafenib in patients with relapsed or refractory lymphoma (2012) (38)
Noninvasive Molecular Monitoring in Multiple Myeloma Patients Using Cell-Free Tumor DNA: A Pilot Study. (2018) (38)
Pretransplantation [18‐F]fluorodeoxyglucose positron emission tomography scan predicts outcome in patients with recurrent Hodgkin lymphoma or aggressive non‐Hodgkin lymphoma undergoing reduced‐intensity conditioning followed by allogeneic stem cell transplantation (2010) (37)
Integrative analysis of the genomic and transcriptomic landscape of double-refractory multiple myeloma. (2020) (36)
Rearrangements of the BCL 6 Gene in Diffuse Large Cell Non-Hodgkin ’ s Lymphoma (2000) (36)
The CIBMTR score predicts survival of AML patients undergoing allogeneic transplantation with active disease after a myeloablative or reduced intensity conditioning: a retrospective analysis of the Gruppo Italiano Trapianto Di Midollo Osseo (2013) (35)
A phase II study on the role of gemcitabine plus romidepsin (GEMRO regimen) in the treatment of relapsed/refractory peripheral T-cell lymphoma patients (2016) (35)
N- and K-ras oncogenes in plasma cell dyscrasias. (1994) (34)
Post-transplant cyclophosphamide, a promising anti-graft versus host disease prophylaxis: where do we stand? (2017) (34)
Maintenance Therapies for Hodgkin and Non-Hodgkin Lymphomas After Autologous Transplantation: A Consensus Project of ASBMT, CIBMTR, and the Lymphoma Working Party of EBMT (2019) (34)
Bendamustine for Hodgkin lymphoma patients failing autologous or autologous and allogeneic stem cell transplantation: a retrospective study of the Fondazione Italiana Linfomi (2014) (33)
Peripheral blood or bone marrow cells in reduced-intensity or myeloablative conditioning allogeneic HLA identical sibling donor transplantation for multiple myeloma (2007) (33)
Addition of Rituximab to Involved-Field Radiation Therapy Prolongs Progression-free Survival in Stage I-II Follicular Lymphoma: Results of a Multicenter Study. (2016) (33)
Human homologue of Moloney leukemia virus integration-4 locus (MLVI-4), located 20 kilobases 3' of the myc gene, is rearranged in multiple myelomas. (1990) (33)
Extracorporeal Photopheresis for Treatment of Acute and Chronic Graft Versus Host Disease: An Italian Multicentric Retrospective Analysis on 94 Patients on Behalf of the Gruppo Italiano Trapianto di Midollo Osseo. (2016) (32)
Clinical and molecular remission after allogeneic blood cell transplantation in a patient with mantle‐cell lymphoma (1996) (31)
A Phase III Study Of ASCT Vs Cyclophosphamide-Lenalidomide-Dexamethasone and Lenalidomide-Prednisone Maintenance Vs Lenalidomide Alone In Newly Diagnosed Myeloma Patients (2013) (31)
Thalidomide and thrombosis in patients with multiple myeloma. (2001) (31)
Allogeneic transplantation after PD-1 blockade for classic Hodgkin lymphoma (2021) (30)
Brentuximab vedotin in patients with Hodgkin lymphoma and a failed allogeneic stem cell transplantation: results from a named patient program at four Italian centers. (2015) (30)
Phase II Study of Perifosine and Sorafenib Dual-Targeted Therapy in Patients with Relapsed or Refractory Lymphoproliferative Diseases (2014) (30)
SIE, SIES, GITMO evidence-based guidelines on novel agents (thalidomide, bortezomib, and lenalidomide) in the treatment of multiple myeloma (2012) (30)
Melphalan/Prednisone/Lenalidomide (MPR) Versus High-Dose Melphalan and Autologous Transplantation (MEL200) in Newly Diagnosed Multiple Myeloma (MM) Patients <65 Years: Results of a Randomized Phase III Study (2011) (30)
First salvage treatment with bendamustine and brentuximab vedotin in Hodgkin lymphoma: a phase 2 study of the Fondazione Italiana Linfomi (2019) (29)
Daratumumab, Bortezomib, and Dexamethasone (DVd) Versus Bortezomib and Dexamethasone (Vd) in Relapsed or Refractory Multiple Myeloma (RRMM): Updated Efficacy and Safety Analysis of Castor (2017) (29)
Elimination of bcl-2-IgH-positive follicular lymphoma cells from blood transplants with high recovery of hematopoietic progenitors by the miltenyi CD34+ cell sorting system. (1996) (28)
Peripheral blood CD34+ cell monitoring after cyclophosphamide and granulocyte-colony-stimulating factor: an algorithm for the pre-emptive use of plerixafor (2014) (28)
High-dose mitoxantrone + melphalan (MITO/L-PAM) as conditioning regimen supported by peripheral blood progenitor cell (PBPC) autograft in 113 lymphoma patients: high tolerability with reversible cardiotoxicity (2001) (28)
Efficacy and Safety of Daratumumab, Bortezomib, and Dexamethasone (D-Vd) Versus Bortezomib and Dexamethasone (Vd) in First Relapse Patients (pts) with Multiple Myeloma (MM): Four-Year Update of Castor (2019) (28)
Experts’ considerations on HLA‐haploidentical stem cell transplantation (2014) (27)
Hemopoietic Progenitor Cell Mobilization and Harvest Following an Intensive Chemotherapy Debulking in Indolent Lymphoma Patients (1999) (27)
Update on a Phase III Study of Panobinostat with Bortezomib and Dexamethasone in Patients with Relapsed Multiple Myeloma: PANORAMA 1, (2011) (27)
Reduced intensity conditioning with thiotepa, fludarabine, and melphalan is effective in advanced multiple myeloma (2007) (26)
Outcome of paraosseous extra-medullary disease in newly diagnosed multiple myeloma patients treated with new drugs (2019) (26)
CD52 antigen expressed by malignant plasma cells can be targeted by alemtuzumab in vivo in NOD/SCID mice. (2006) (26)
Unrelated donor haematopoietic cell transplantation after non‐myeloablative conditioning for patients with high‐risk multiple myeloma (2007) (26)
Daratumumab, bortezomib, and dexamethasone in relapsed or refractory multiple myeloma: subgroup analysis of CASTOR based on cytogenetic risk (2020) (26)
Circulating miRNA panel for prediction of acute graft-versus-host disease in lymphoma patients undergoing matched unrelated hematopoietic stem cell transplantation. (2016) (26)
Bortezomib-Doxorubicin-Dexamethasone as Induction Prior to Reduced Intensity Autologous Transplantation Followed by Lenalidomide as Consolidation/Maintenance in Elderly Untreated Myeloma Patients (2008) (26)
Dose/Schedule-Adjusted Rd-R vs Continuous Rd for elderly, intermediate-fit, newly diagnosed multiple myeloma patients. (2021) (25)
Myc Expression and Tumor-Infiltrating T Cells Are Associated with Response in Patients (Pts) with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (r/r DLBCL) Treated with Tisagenlecleucel in the Juliet Trial (2020) (25)
A prognostic model for patients with lymphoma and COVID-19: a multicentre cohort study (2021) (25)
Use of intrathecal prophylaxis in allogeneic haematopoietic stem cell transplantation for malignant blood diseases: a survey of the European Group for Blood and Marrow Transplantation (EBMT) (2005) (25)
Predicting failure of hematopoietic stem cell mobilization before it starts: the predicted poor mobilizer (pPM) score (2018) (24)
Dose-adjusted EPOCH plus rituximab improves the clinical outcome of young patients affected by double expressor diffuse large B-cell lymphoma (2019) (24)
Phase 1/2 study of weekly carfilzomib, cyclophosphamide, dexamethasone in newly diagnosed transplant-ineligible myeloma (2018) (24)
Correlative Analyses of Patient and Clinical Characteristics Associated with Efficacy in Tisagenlecleucel-Treated Relapsed/Refractory Diffuse Large B-Cell Lymphoma Patients in the Juliet Trial (2019) (24)
Bortezomib plus dexamethasone followed by escalating donor lymphocyte infusions for patients with multiple myeloma relapsing or progressing after allogeneic stem cell transplantation. (2013) (24)
Tandem Autologous(ASCT)/ Allogeneic Reduced Intensity Conditioning Transplantation (RIC) with Identical Sibling Donor Versus ASCT in Previously Untreated Multiple Myeloma (MM): Long Term Follow up of a Prospective Controlled Trial by the EBMT. (2009) (23)
How many chronic myeloid leukemia patients who started a frontline second‐generation tyrosine kinase inhibitor have to switch to a second‐line treatment? A retrospective analysis from the monitoring registries of the italian medicines agency (AIFA) (2020) (23)
Haploidentical Allogeneic Hematopoietic Cell Transplantation for Multiple Myeloma Using Post-Transplantation Cyclophosphamide Graft-versus-Host Disease Prophylaxis. (2017) (23)
Autoimmune diseases during treatment with immunomodulatory drugs in multiple myeloma: selective occurrence after lenalidomide (2014) (22)
Carfilzomib, Pomalidomide and Dexamethasone (KPd) in Patients with Multiple Myeloma Refractory to Bortezomib and Lenalidomide. the EMN011 Trial (2018) (22)
Haematological support of high-dose sequential chemotherapy: clinical evidence for reduction of toxicity and high response rates in poor risk lymphomas. (1995) (22)
Considerations in the treatment of multiple myeloma: a consensus statement from Italian experts (2009) (21)
Melflufen or pomalidomide plus dexamethasone for patients with multiple myeloma refractory to lenalidomide (OCEAN): a randomised, head-to-head, open-label, phase 3 study. (2022) (21)
Prolonged survival and low incidence of late toxic sequelae in advanced follicular lymphoma treated with a TBI-free autografting program: updated results of the multicenter consecutive GITMO trial (2006) (21)
Brentuximab vedotin prior to allogeneic stem cell transplantation in Hodgkin lymphoma: a report from the EBMT Lymphoma Working Party (2018) (21)
Allogeneic hematopoietic cell transplantation from unrelated donors in multiple myeloma: study from the Italian Bone Marrow Donor Registry. (2013) (21)
Randomized trial comparing standard vs sequential high-dose chemotherapy for inducing early CR in adult AML. (2019) (20)
Multiple myeloma: reduced plasma cell contamination in peripheral blood progenitor cell collections performed after repeated high‐dose chemotherapy courses (1997) (20)
CD3+ graft cell count influence on chronic GVHD in haploidentical allogeneic transplantation using post-transplant cyclophosphamide (2018) (19)
Safety and efficacy of single-agent bendamustine after failure of brentuximab vedotin in patients with relapsed or refractory hodgkin's lymphoma: experience with 27 patients. (2015) (19)
Dose-Reduced Conditioning Followed by Allogeneic Stem Cell Transplantation in Patients with Myelofibrosis. Results from a Multicenter Prospective Trial of the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). (2007) (19)
EPICOVIDEHA: A Ready to Use Platform for Epidemiological Studies in Hematological Patients With COVID-19 (2021) (18)
Early reduction of serum TARC levels may predict for success of ABVD as frontline treatment in patients with Hodgkin Lymphoma. (2017) (18)
RESPONSE ORIENTED MAINTENANCE THERAPY IN ADVANCED FOLLICULAR LYMPHOMA. RESULTS OF THE INTERIM ANALYSIS OF THE FOLL12 TRIAL CONDUCTED BY THE FONDAZIONE ITALIANA LINFOMI. (2019) (18)
Adverse event management in patients with relapsed and refractory multiple myeloma taking pomalidomide plus low‐dose dexamethasone: A pooled analysis (2017) (18)
Efficacy and Safety of Retreatment with Bortezomib in Patients with Multiple Myeloma: Interim Results From RETRIEVE, a Prospective International Phase 2 Study. (2009) (18)
COVID-19 and CAR T cells: a report on current challenges and future directions from the EPICOVIDEHA survey by EHA-IDWP (2021) (18)
Previous thalidomide therapy may not affect lenalidomide response and outcome in relapse or refractory multiple myeloma patients. (2011) (18)
Long-Term Follow-up of Patients Affected by Relapsed Lymphomas Receiving Reduced-Intensity Conditioning (RIC) Regimen Followed by Allogeneic Stem Cell Transplantation (Allo-SCT): An Update of the Phase II Study of the Gruppo Italiano Trapianto Di Midollo Osseo (GITMO) (2008) (18)
Recurrence of Bcl-2/IgH polymerase chain reaction positivity following a prolonged molecular remission can be unrelated to the original follicular lymphoma clone. (2003) (18)
Current status of haematopoietic autologous stem cell transplantation in lymphoid malignancies: a European perspective (2015) (17)
Impressive Response to Dose-Dense Chemotherapy in a Patient with NUT Midline Carcinoma (2015) (17)
Managing hematological cancer patients during the COVID-19 pandemic: an ESMO-EHA Interdisciplinary Expert Consensus (2022) (17)
A Randomized Phase 3 Trial Of Melphalan-Lenalidomide-Prednisone (MPR) Or Cyclophosphamide-Prednisone-Lenalidomide (CPR) Vs Lenalidomide Plus Dexamethsone (Rd) In Elderly Newly Diagnosed Multiple Myeloma Patients (2013) (17)
Allogeneic transplantation for Hodgkin’s lymphoma (2011) (17)
Pomalidomide Cyclophosphamide and Prednisone (PCP) Treatment for Relapsed/Refractory Multiple Myeloma (2012) (17)
Allogeneic transplantation for multiple myeloma (2009) (17)
SIE-SIES-GITMO guidelines for the management of adult peripheral T- and NK-cell lymphomas, excluding mature T-cell leukaemias. (2014) (17)
Safety, Tolerability and Activity of Ofatumumab, Bendamustine and Dexamethasone Combination As First-Line Treatment of Mantle-Cell Lymphoma in the Elderly: A Multicenter Study (2011) (17)
Long‐term patterns of humoral and cellular response after vaccination against influenza A (H1N1) in patients with hematologic malignancies (2012) (16)
Autologous stem cell transplantation for T-cell lymphomas. (2014) (16)
Correlation of Bridging and Lymphodepleting Chemotherapy with Clinical Outcomes in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma Treated with Tisagenlecleucel (2019) (16)
IFN-gamma enhances the antimyeloma activity of the fully human anti-human leukocyte antigen-DR monoclonal antibody 1D09C3. (2007) (15)
A Phase I/II Study of Pomalidomide-Cyclophosphamide-Prednisone (PCP) in Patients with Multiple Myeloma Relapsed/Refractory to Lenalidomide (2011) (15)
Brentuximab vedotin for recurrent Hodgkin lymphoma after allogeneic hematopoietic stem cell transplantation: A report from the EBMT Lymphoma Working Party (2018) (15)
Outcome of patients activating an unrelated donor search: the impact of transplant with reduced intensity conditioning in a large cohort of consecutive high-risk patients (2012) (15)
A Prospective, Randomized Study of Melphalan, Prednisone, Lenalidomide (MPR) versus Melphalan (200 Mg/M 2 ) and Autologous Transplantation (Mel200) in Newly Diagnosed Myeloma Patients: An Interim Analysis. (2009) (15)
Impact of CR before and after allogeneic and autologous transplantation in multiple myeloma: results from the EBMT NMAM2000 prospective trial (2015) (15)
Clinical Activity of Lucatumumab (HCD122) In Patients (pts) with Relapsed/Refractory Hodgkin or Non-Hodgkin Lymphoma Treated In a Phase Ia/II Clinical Trial (NCT00670592) (2010) (14)
Peripheral blood progenitor cell mobilization in patients with primary refractory lymphoma or at first relapse: comparison with patients at diagnosis and impact on clinical outcome (1997) (14)
Handling the COVID-19 pandemic in the oncological setting (2020) (14)
Breakthrough COVID-19 in vaccinated patients with hematologic malignancies: results from the EPICOVIDEHA survey (2022) (14)
Long-term follow-up of metastatic renal cancer patients undergoing reduced-intensity allografting (2009) (14)
Glofitamab for Relapsed or Refractory Diffuse Large B-Cell Lymphoma. (2022) (14)
Long-Term Follow-Up of a Donor versus No-Donor Comparison in Patients with Multiple Myeloma in First Relapse after Failing Autologous Transplantation. (2018) (14)
Brentuximab Vedotin in CD30-Positive Lymphomas: A SIE, SIES, and GITMO Position Paper. (2015) (14)
Pomalidomide + Low-Dose Dexamethasone in Patients with Refractory or Relapsed and Refractory Multiple Myeloma and Renal Impairment: Analysis of Patients from the Phase 3b Stratus Trial (MM-010) (2014) (14)
High rate of remission and low rate of disease recurrence in patients with multiple myeloma allografted with PBSC from their HLA-identical sibling donors (2003) (14)
Qualitative and quantitative polymerase chain reaction detection of the residual myeloma cell contamination after positive selection of CD34+ cells with small‐ and large‐scale Miltenyi cell sorting system (2002) (14)
Minimal Residual Disease Evaluation By Multiparameter Flow Cytometry and Next Generation Sequencing in the Forte Trial for Newly Diagnosed Multiple Myeloma Patients (2019) (13)
Comparative assessment of telomere length before and after hematopoietic SCT: role of grafted cells in determining post-transplant telomere status (2010) (13)
Short-term treatment of reflux oesophagitis with ranitidine 300 mg nocte. Italian multicentre study. (1987) (13)
Serum thymus and activation-regulated chemokine level monitoring may predict disease relapse detected by PET scan after reduced-intensity allogeneic stem cell transplantation in patients with Hodgkin lymphoma. (2014) (13)
Real-world evidence of brexucabtagene autoleucel for the treatment of relapsed or refractory mantle cell lymphoma (2021) (13)
Limits and Applications of Genomic Analysis of Circulating Tumor DNA as a Liquid Biopsy in Asymptomatic Forms of Multiple Myeloma (2020) (13)
Overview of alemtuzumab therapy for the treatment of T-cell lymphomas (2012) (13)
Next‐generation sequencing of a family with a high penetrance of monoclonal gammopathies for the identification of candidate risk alleles (2017) (12)
Impact of Bortezomib- or Lenalidomide-Based Induction Treatment on High Risk Cytogenetic Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma Enrolled in the Gimema-MM-03-05 and EMN01 Trials (2017) (12)
Allogeneic stem cell transplantation and subsequent treatments as a comprehensive strategy for long-term survival of multiple myeloma patients (2017) (12)
CDKN2A deletion is a frequent event associated with poor outcome in patients with peripheral T-cell lymphoma not otherwise specified (PTCL-NOS) (2020) (12)
Dual Targeted Therapy with the AKT Inhibitor Perifosine and the Multikinase Inhibitor Sorafenib in Patients with Relapsed/Refractory Lymphomas: Final Results of a Phase II Trial (2012) (12)
Immune reconstitution inflammatory syndrome associated with Aspergillus terreus pulmonary infection in an autologous stem cell transplant recipient (2010) (12)
Italian real life experience with brentuximab vedotin: results of a large observational study on 234 relapsed/refractory Hodgkin's lymphoma. (2017) (12)
Bronchial fibroepithelial polyp: a clinico‐radiologic, bronchoscopic, histopathological and in‐situ hybridisation study of 15 cases of a poorly recognised lesion (2017) (12)
Mutational Activation of Nand Kras Oncogenes in Plasma Cell Dyscrasias (2003) (12)
ISATUXIMAB PLUS POMALIDOMIDE AND DEXAMETHASONE IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA AND SOFT-TISSUE PLASMACYTOMAS: ICARIA-MM SUBGROUP ANALYSIS (2020) (12)
Reduced intensity stem cell transplantation for advanced soft tissue sarcomas in adults: a retrospective analysis of the European Group for Blood and Marrow Transplantation. (2007) (12)
Concomitant therapy with direct-acting antivirals and chemoimmunotherapy in HCV-associated diffuse large B-cell lymphoma. (2019) (11)
Methodological framework for radiomics applications in Hodgkin’s lymphoma (2020) (11)
Ibrutinib as a salvage therapy after allogeneic HCT for chronic lymphocytic leukemia (2019) (11)
Italian real life experience with brentuximab vedotin: results of a large observational study on 234 relapsed/refractory Hodgkin’s lymphoma (2017) (11)
Multiparameter flow cytometry (MFC) and next generation sequencing (NGS) for minimal residual disease (MRD) evaluation: Results of the FORTE trial in newly diagnosed multiple myeloma (MM). (2020) (11)
EXTRACORPOREAL PHOTOPHERESIS (ECP) FOR TREATEMENT OF ACUTE AND CHRONIC GRAFT VERSUS HOST DISEASE: AN ITALIAN MULTICENTRIC RETROSPECTIVE ANALYSIS ON 94 PATIENTS ON BEHALF OF THE GRUPPO ITALIANO TRAPIANTO DI MIDOLLO OSSEO (GITMO). (2016) (11)
What do the people think (and know) about informed consent for participation in a medical trial. (2001) (11)
Dioxin exposure of human CD34+ hemopoietic cells induces gene expression modulation that recapitulates its in vivo clinical and biological effects. (2011) (11)
Allogeneic transplantation for lymphoma: long-term outcome (2010) (11)
Detection of minimal residual disease by real-time PCR can be used as a surrogate marker to evaluate the graft-versus-myeloma effect after allogeneic stem cell transplantation (2003) (11)
Glofitamab (Glofit) in Combination with Polatuzumab Vedotin (Pola): Phase Ib/II Preliminary Data Support Manageable Safety and Encouraging Efficacy in Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) (2021) (10)
Efficacy and Safety of Re-Treatment with Bortezomib (Velcade©) in Patients with Multiple Myeloma: Results from a Prospective International Phase II Trial (2008) (10)
Fear of cancer recurrence in haematological cancer patients: exploring socio-demographic, psychological, existential and disease-related factors (2020) (10)
Dose-adjusted EPOCH and rituximab for the treatment of double expressor and double-hit diffuse large B-cell lymphoma: impact of TP53 mutations on clinical outcome (2021) (10)
Glofitamab in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) and ≥ 2 prior therapies: Pivotal phase II expansion results. (2022) (10)
Critical concepts, practice recommendations, and research perspectives of pixantrone therapy in non‐Hodgkin lymphoma: a SIE, SIES, and GITMO consensus paper (2016) (10)
Humoral and T-cell immune response after three doses of mRNA SARS-CoV-2 vaccines in fragile patients: the Italian VAX4FRAIL study (2022) (10)
Lenalidomide can induce long-term responses in patients with multiple myeloma relapsing after multiple chemotherapy lines, in particular after allogeneic transplant (2011) (10)
High Levels of Circulating Tumor Plasma Cells as a Key Hallmark of Aggressive Disease in Transplant-Eligible Patients With Newly Diagnosed Multiple Myeloma (2022) (9)
Plerixafor ‘on demand’: results of a strategy based on peripheral blood CD34+ cells in lymphoma patients at first or subsequent mobilization with chemotherapy+G-CSF (2014) (9)
Sequential Brief Chemo-Immunotherapy FND + Rituximab in Elderly Patients with Advanced Stage Follicular Lymphoma (FL): High Clinical and Molecular Remission Rate Associated with a Prolonged Failure-Free Survival. (2004) (9)
A Prospective, Randomized, Phase III Study of Enoxaparin Versus Aspirin Versus Low-Fixed-Dose of Warfarin in Newly Diagnosed Myeloma Patients Treated with Thalidomide-Containing Regimens. (2007) (9)
Oral RevlimidR Plus Melphalan and Prednisone (R-MP) for Newly Diagnosed Multiple Myeloma. (2005) (9)
PANORAMA1: A randomized, double-blind, placebo controlled phase III study of panobinostat in combination with bortezomib and dexamethasone in patients with relapsed multiple myeloma. (2011) (9)
Influence of temperature on the production of antibiotic molecules in Bacillus amyloliquefaciens strain HNA3. (2011) (9)
Integration of transcriptional and mutational data simplifies the stratification of peripheral T‐cell lymphoma (2019) (9)
Haploidentical related donor compared to HLA-identical donor transplantation for chemosensitive Hodgkin lymphoma patients (2020) (9)
Polatuzumab Vedotin Plus Venetoclax with Rituximab in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Primary Efficacy Analysis of a Phase Ib/II Study (2020) (9)
Increased leukocyte aggregation in patients with hypercholesterolaemia. (1984) (9)
Italian real-life experience with brentuximab vedotin: results of a large observational study of 40 cases of relapsed/refractory systemic anaplastic large cell lymphoma (2017) (9)
Gay F, Magarotto V, Crippa C, et al. Bortezomib induction, reduced-intensity transplantation, and lenalidomide consolidation-maintenance for myeloma: Updated results. (Blood (2013) 122, 8 (1376-1383)) (2014) (9)
Clinical significance of chromatin-spliceosome acute myeloid leukemia: a report from the Northern Italy Leukemia Group (NILG) randomized trial 02/06 (2020) (9)
Mortality rate in patients with chronic myeloid leukemia in chronic phase treated with frontline second generation tyrosine kinase inhibitors: a retrospective analysis by the monitoring registries of the Italian Medicines Agency (AIFA) (2021) (9)
High-dose chemotherapy followed by autologous transplantation may overcome the poor prognosis of diffuse large B-cell lymphoma patients with MYC/BCL2 co-expression (2016) (9)
Are We Ready to Treat Diffuse Large B-cell and High-Grade Lymphoma According to Major Genetic Subtypes? (2019) (9)
Outcomes of haploidentical stem cell transplantation for chronic lymphocytic leukemia: a retrospective study on behalf of the chronic malignancies working party of the EBMT (2018) (8)
Phase II Trial of Combination of the Histone Deacetylase Inhibitor ITF2357 and Meclorethamine Demonstrates Clinical Activity and Safety in Heavily Pretreated Patients with Relapsed/Refractory Hodgkin Lymphoma (HL) (2008) (8)
Prolonged survival in the absence of disease-recurrence in advanced-stage follicular lymphoma following chemo-immunotherapy: 13-year update of the prospective, multicenter randomized GITMO-IIL trial (2019) (8)
Bortezomib, Pegylated-Lyposomal-Doxorubicin and Dexamethasone Followed by Melphalan 100 mg/m2 in Elderly Newly Diagnosed Patients: An Interim Analysis. (2007) (8)
Allogeneic Stem Cell Transplantation for Relapsed/Refractory B Cell Lymphomas: Results of a Multicenter Phase II Prospective Trial including Rituximab in the Reduced-Intensity Conditioning Regimen. (2017) (8)
Analysis of the immunoglobulin heavy-chain gene rearrangement providing molecular evidence of second lymphoma in a patient in apparent relapse after autotransplantation (1997) (8)
Antibiotic Prophylaxis Before Dental Procedures Can Reduce ONJ Incidence. (2007) (8)
Lamivudine prophylaxis prevents hepatitis B virus reactivation in anti-HBc positive patients under rituximab for non-Hodgkin lymphoma. (2019) (8)
CORRELATIVE ANALYSES OF CYTOKINE RELEASE SYNDROME AND NEUROLOGICAL EVENTS IN TISAGENLECLEUCEL‐TREATED RELAPSED/REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA PATIENTS (2019) (8)
Bortezomib, pegylated-lyposomal-doxorubicin and dexamethasone (PAD) as induction therapy prior to reduced intensity autologous stem cell transplant (ASCT) followed by lenalidomide and prednisone (LP) as consolidation and lenalidomide alone as maintenance (2008) (8)
Safety and Efficacy of Allogeneic Hematopoietic Stem Cell Transplant after Programmed Cell Death 1 (PD-1) / Programmed Cell Death Ligand 1 (PD-L1) Blockade for Classical Hodgkin Lymphoma: Analysis of a Large International Cohort (2019) (8)
Rapid Antibody Testing for SARS-CoV-2 in Asymptomatic and Paucisymptomatic Healthcare Professionals in Hematology and Oncology Units Identifies Undiagnosed Infections (2020) (8)
[Metadoxine in alcohol-related pathology]. (1989) (8)
Outcome of allogeneic transplantation for mature T-cell lymphomas: impact of donor source and disease characteristics (2021) (8)
Impact of Minimal Residual Disease (MRD) By Multiparameter Flow Cytometry (MFC) and Next-Generation Sequencing (NGS) on Outcome: Results of Newly Diagnosed Transplant-Eligible Multiple Myeloma (MM) Patients Enrolled in the Forte Trial (2020) (8)
Response‐adjusted ISS (RaISS) is a simple and reliable prognostic scoring system for predicting progression‐free survival in transplanted patients with multiple myeloma (2012) (8)
Treatment Intensification With Autologous Stem Cell Transplantation and Lenalidomide Maintenance Improves Survival Outcomes of Patients With Newly Diagnosed Multiple Myeloma in Complete Response (2018) (8)
Reduced-Intensity Conditioning (RIC) Followed by Allogeneic Transplantation in Relapsed Lymphomas: Evidence for Graft-Versus-Lymphoma Effect in Low and High Grade Histologies, but Not in Hodgkin Disease. (2004) (7)
Failure of long-term lamivudine prophylaxis in patients with resolved hepatitis B infection undergoing chemotherapy and allogenic hematopoietic stem cell transplantation for hematological malignancies: two case reports (2017) (7)
Update of a GITIL Cohort Study: Frontline High Dose Sequential Chemotherapy with Rituximab and Autologous Stem Cell Transplantation Induces a High Rate of Long-Term Remissions in Patients with Mantle Cell Lymphoma (2007) (7)
Analysis of immunoglobulin heavy chain gene rearrangement using the polymerase chain reaction. (1992) (7)
Imatinib Is Safe and Effective In Patients with Refractory Chronic Graft Versus Host Disease: Analysis of Two Consecutive Prospective GITMO* Studies.*Gruppo Italiano Trapianto Midollo Osseo (2010) (7)
Measurement by bioluminescence technique of erythrocyte membrane Na+,K+-ATPase activity in hypertensive patients. (1987) (7)
PATIENT VOICES, a project for the integration of the systematic assessment of patient reported outcomes and experiences within a comprehensive cancer center: a protocol for a mixed method feasibility study (2020) (7)
Autologous Transplantation Versus Cyclophosphamide-Lenalidomide-Prednisone Followed By Lenalidomide-Prednisone Versus Lenalidomide Maintenance in Multiple Myeloma: Long-Term Results of a Phase III Trial (2015) (7)
Bortezomib, cyclophosphamide, dexamethasone versus lenalidomide, cyclophosphamide, dexamethasone in multiple myeloma patients at first relapse (2017) (7)
Chemoimmunotherapy with R-CHOP or High Dose Sequential Therapy with Autologous Stem Cell Transplantation (R-HDS) for High Risk Diffuse Large B-Cell Lymphomas Patients: Results of the Randomized R-HDS0305 Trial by Gruppo Italiano Terapie Innovative Nei Linfomi (GITIL) (2012) (7)
Traumatic neuroma of the bronchi: bronchoscopy and histology of a hitherto unreported lesion. (2008) (7)
Efficacy and Safety of Daratumumab, Bortezomib, and Dexamethasone (D-Vd) Versus Bortezomib and Dexamethasone (Vd) in First Relapse Patients: Two-Year Update of Castor (2018) (7)
Allogeneic transplantation for relapsed and refractory Hodgkin lymphoma: long-term outcomes and graft-versus-host disease-free/relapse-free survival (2019) (7)
Immune-mediated attack in relapsed Hodgkin's lymphoma (2005) (7)
Impact of Tisagenlecleucel Chimeric Antigen Receptor (CAR)-T Cell Therapy Product Attributes on Clinical Outcomes in Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (r/r DLBCL) (2019) (7)
Early serum TARC reduction predicts prognosis in advanced‐stage Hodgkin lymphoma patients treated with a PET‐adapted strategy (2020) (7)
The neutrophil to lymphocyte ratio (NLR) and the presence of large nodal mass are independent predictors of early response: A subanalysis of the prospective phase II PET‐2‐adapted HD0607 trial (2020) (7)
EARLY STAGE Follicular Lymphoma: First Results of the FIL "Miro" Study, a Multicenter Phase II Trial Combining Local Radiotherapy and MRD-Driven Immunotherapy (2019) (7)
Central Nervous System Relapse in a Patient with Mantle Cell Lymphoma in Continuous Clinical and Molecular Remission at Six Years Since Autografting (2001) (7)
Oral Melphalan, Prednisone, and Lenalidomide for Newly Diagnosed Multiple Myeloma Patients: Kinetics of Neutropenia/Thrombocytopenia and Time to Event Results (2008) (7)
Maintenance in myeloma patients achieving complete response after upfront therapy: a pooled analysis (2018) (7)
Carfilzomib, bendamustine, and dexamethasone (KBd) in advanced multiple myeloma: The EMN09-trial. (2018) (7)
Weekly Carfilzomib, Cyclophosphamide and Dexamethasone (wCCd) in Newly Diagnosed Multiple Myeloma Patients: A Phase I- II Study (2014) (7)
Avadomide (CC-122), a Novel Cereblon Modulating Agent, Plus Rituximab in Patients with Relapsed or Refractory Follicular Lymphoma (2018) (7)
Humoral and T-Cell Immune Response After 3 Doses of Messenger RNA Severe Acute Respiratory Syndrome Coronavirus 2 Vaccines in Fragile Patients: The Italian VAX4FRAIL Study (2022) (6)
Preliminary Results of a Phase II Trial with the Multikinase Inhibitor Sorafenib in Heavily Pretreated Patients with Relapsed/Refractory Non-Hodgkin Lymphoma (NHL). (2009) (6)
Glofitamab As Monotherapy and in Combination with Obinutuzumab Induces High Complete Response Rates in Patients (pts) with Multiple Relapsed or Refractory (R/R) Follicular Lymphoma (FL) (2021) (6)
Cardio-vascular Toxicity in Newly Diagnosed, Transplant-ineligible Multiple Myeloma Patients Treated With Carfilzomib, Cyclophosphamide and Dexamethasone: Results From an Integrated Analysis of 3 Phase I/II Trials (2017) (6)
Tyrosine kinase inhibition to improve anthracycline-based chemotherapy efficacy in T-cell lymphoma (2019) (6)
Functional Impact of Genomic Complexity on the Transcriptome of Multiple Myeloma (2021) (6)
Clinical Activity and Safety of the Combined Therapy with the AKT Inhibitor Perifosine and the Multikinase Inhibitor Sorafenib In Heavily Pretreated Patients with Relapsed/Refractory Lymphomas: Preliminary Results of a Phase II Trial (2010) (6)
Carfilzomib in Combination with Bendamustine and Dexamethasone (CBd) in Relapsed and/or Refractory Patients with Multiple Myeloma: The Phase I/II EMN09 Study (2016) (6)
Nizatidine in the short-term treatment of duodenal ulcer--an Italian Multicenter Study. (1987) (6)
Dual rearrangement of immunoglobulin and T‐cell receptor gene in a case of T‐cell hairy‐cell leukemia (1991) (6)
Improved Clinical Outcome of COVID-19 in Hematologic Malignancy Patients Receiving a Fourth Dose of Anti-SARS-CoV-2 Vaccine: An EPICOVIDEHA Report (2022) (6)
Safety and ef fi cacy of pomalidomide plus low-dose dexamethasone in STRATUS ( MM-010 ) : a phase 3 b study in refractory multiple myeloma (2016) (5)
Management of chronic myeloid leukaemia patients treated with ponatinib in a real‐life setting: A retrospective analysis from the monitoring registries of the Italian Medicines Agency (AIFA) (2022) (5)
Long-term follow-up of metastatic renal cancer patients undergoing reduced-intensity allografting. (2009) (5)
Safety and Efficacy in the Stratus (MM-010) Trial, a Single-Arm Phase 3b Study Evaluating Pomalidomide + Low-Dose Dexamethasone in Patients with Refractory or Relapsed and Refractory Multiple Myeloma (2014) (5)
Analysis of the breakpoint cluster region in essential thrombocythemia. (1990) (5)
Bortezomib after allografting in multiple myeloma: association between neurotoxicity and cyclosporine treatment. (2007) (5)
Total body irradiation + fludarabine compared to busulfan + fludarabine as “reduced-toxicity conditioning” for patients with acute myeloid leukemia treated with allogeneic hematopoietic cell transplantation in first complete remission: a study by the Acute Leukemia Working Party of the EBMT (2020) (5)
Haplotransplants Versus Other Alternative Donors for Allogeneic Stem Cell Transplantation in Non Hodgkin Lymphoma (NHL): A Retrospective Analysis of the EBMT Lymphoma Working Party (2014) (5)
COVID-19 in adult acute myeloid leukemia patients: a long-term follow-up study from the European Hematology Association survey (EPICOVIDEHA) (2022) (5)
Real-life feasibility of salvage allogeneic transplantation in peripheral T-cell lymphomas (2018) (5)
Long Term Follow-up of the Prospective Multicenter Study of reduced-Intensity Allogeneic Stem Cell Transplantation for Primary or Post ET/PV Myelofibrosis (2011) (5)
Autologous stem cell transplantation (ASCT) vs ASCT followed by reduced-intensity conditioning allogeneic SCT with identical sibling donor in previously untreated multiple myeloma: preliminary analysis of a prospective controlled trial by the EBMT (2008) (5)
Impact of Autologous Transplantation Vs. Chemotherapy Plus Lenalidomide in Newly Diagnosed Myeloma According to Patient Prognosis: Results of a Pooled Analysis of 2 Phase III Trials (2014) (5)
The Role of Autologous and Allogeneic Stem Cell Transplantation in Follicular Lymphoma in The New Drugs Era (2016) (5)
Prolonged Survival Of Poor Risk Follicular Lymphoma Patients Following Primary Treatment With Rituximab-Supplemented CHOP Or HDS With Autograft: Long-Term Results Of The Multicenter Randomized GITMO/FIL Trial (2013) (5)
Nilotinib in steroid-refractory cGVHD: prospective parallel evaluation of response, according to NIH criteria and exploratory response criteria (GITMO criteria) (2020) (5)
A brief rituximab, bendamustine, mitoxantrone (R‐BM) induction followed by rituximab consolidation in elderly patients with advanced follicular lymphoma: a phase II study by the Fondazione Italiana Linfomi (FIL) (2021) (5)
Late Relapse in Hodgkin Lymphoma (HL): A Retrospective Analysis of Patients Enrolled on Clinical Trials at the Istituto Nazionale Tumori of Milan (INT-MI) (2015) (5)
A three-gene signature based on MYC, BCL-2 and NFKBIA improves risk stratification in diffuse large B-cell lymphoma (2020) (5)
Chemotherapy after PD‐1 inhibitors in relapsed/refractory Hodgkin lymphoma: Outcomes and clonal evolution dynamics (2022) (5)
Recurrent Hodgkin lymphoma: toward a new definition of candidates for autologous stem cell transplant in the era of positron emission tomography scan and novel agents (2015) (5)
Phenotypic Composition of Commercial Anti-CD19 CAR T Cells Affects In Vivo Expansion and Disease Response in Patients with Large B-cell Lymphoma (2022) (5)
Romidepsin in relapsed/refractory T-cell lymphomas: Italian experience and results of a named patient program (2016) (5)
Phase III study of panobinostat with bortezomib and dexamethasone in patients with relapsed multiple myeloma (PANORAMA 1). (2012) (5)
Role of stem cell transplantation in myeloma (2005) (4)
Analysis of Mutational Signatures Suggest That Aid Has an Early and Driver Role in Multiple Myeloma (2016) (4)
Ocular disorders in multiple myeloma patients: cross-sectional study of prevalence and association with treatment (2018) (4)
Benefit of Rituximab Addition to High-Dose Programs with Autograft for B-Cell Lymphoma: A Multicenter GITIL Survey on 957 Patients. (2006) (4)
Prognostic Value of Positron Emission Tomography (PET) Scan in Patients with Relapsed Hodgkin Lymphoma or Aggressive Non-Hodgkin Lymphoma Receiving Salvage Chemotherapy Followed by Reduced-Intensity Allogeneic Stem Cell Transplantation. (2007) (4)
PCR-based monitoring of residual myeloma cells in patients undergoing high-dose chemotherapy (1998) (4)
Tandem autologous-reduced intensity allogeneic stem cell transplantation in high-risk relapsed Hodgkin lymphoma: a retrospective study of the Lymphoma Working Party—EBMT (2020) (4)
Clinical and Molecular Results of the Multicenter Randomized GITMO-IIL Trial in Poor Risk Follicular Lymphoma (FL) at Diagnosis: Rituximab-Supplemented High-Dose Sequential Chemotherapy (R-HDS) Is Superior to CHOP-R in Molecular Remissions Rate, EFS and PFS. (2006) (4)
Refractory and 17p-deleted chronic lymphocytic leukemia: improving survival with pathway inhibitors and allogeneic stem cell transplantation. (2020) (4)
Carfilzomib, Pomalidomide and Dexamethasone (KPd) in Patients with First Progression of Multiple Myeloma Refractory to Bortezomib and Lenalidomide. Final Report of the EMN011/HOVON114 Trial (2021) (4)
Molecular Subtypes of Splenic Marginal Zone Lymphoma (SMZL) Are Associated with Distinct Pathogenic Mechanisms and Outcomes - Interim Analysis of the IELSG46 Study (2018) (4)
High Throughput Molecular Characterization of Normal Karyotype Acute Myeloid Leukemia in the Context of the Prospective Trial 02/06 of the Northern Italy Leukemia Group (NILG) (2020) (4)
Bendamustine for Relapsed/Refractory Classical Hodgkin Lymphoma After High Dose Chemotherapy and or Allogeneic Transplant: A Study of Fondazione Italiana Linfomi (FIL) (2012) (4)
Weekly Carfilzomib, Cyclophosphamide and Dexamethasone (wCCyd) in Elderly Newly Diagnosed Multiple Myeloma Patients: Results of a Phase 2 Study (2015) (4)
Lamivudine prophylaxis prevents hepatitis b reactivation in HBsAg-negative/anti-HBc-positive patients undergoing Rituximab-based chemotherapy for non–hodgkin's B cell lymphoma (2015) (4)
Adding Romidepsin to CHOEP in First Line Treatment of Peripheral T-Cell Lymphomas Does Not Improve the Response Rate: Final Analysis of Phase II PTCL13 Study (2021) (4)
Treatment of classical Hodgkin lymphoma in the era of brentuximab vedotin and immune checkpoint inhibitors (2018) (4)
Romidepsin-CHOEP Plus Intensification with up-Front Stem-Cell Transplantation in Peripheral T-Cell Lymphoma: Final Results of Phase Ib PTCL13 Study of the Fondazione Italiana Linfomi (2018) (4)
An Updated Analysis of the Stratus Trial (MM-010): Safety and Efficacy of Pomalidomide Plus Low-Dose Dexamethasone (POM + LoDEX) in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM) (2015) (4)
Analysis of the genomic landscape of multiple myeloma highlights novel prognostic markers and disease subgroups. (2017) (4)
ANALYSIS OF PATIENTS WITH REFRACTORY OR RELAPSED AND REFRACTORY MULTIPLE MYELOMA AND RENAL IMPAIRMENT TREATED WITH POMALIDOMIDE plus LOW-DOSE DEXAMETHASONE IN THE PHASE 3B STRATUS TRIAL (MM-010) (2015) (3)
Polatuzumab vedotin + obinutuzumab + venetoclax in patients with relapsed/refractory (R/R) follicular lymphoma (FL): Primary analysis of a phase 1b/2 trial. (2021) (3)
Dose-Adjusted EPOCH and Rituximab (DA-EPOCH-R) Treatment in Dual Expressor Diffuse Large B-Cell and Double/Triple Hit Lymphomas: TP53 Mutations Influence on Clinical Outcome (2019) (3)
INTRAVENOUS IMMUNOGLOBULIN THERAPY USE IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA TREATED WITH TISAGENLECLEUCEL IN THE JULIET TRIAL (2019) (3)
Venetoclax Shows Low Therapeutic Activity in BCL2-Positive Relapsed/Refractory Peripheral T-Cell Lymphoma: A Phase 2 Study of the Fondazione Italiana Linfomi (2021) (3)
Real-Life CAR-T Cell Treatment in Large B-Cell Lymphomas Indicates That Axi-Cel and Tisa-Cel Have Similar Outcomes, but Long-Term Cytopenia Is an Emerging Problem (2021) (3)
Italian expert panel consensus statement on the optimal use of PD-1 blockade therapy in classical Hodgkin lymphoma (2018) (3)
Spectrin extractability from erythrocytes in Duchenne muscular dystrophy patients and carriers and in other myopathies. (1985) (3)
The Impact of Allogeneic Hematopoietic Stem Cell Transplantation in Children and Adolescents with Recurring Hodgkin’s Lymphoma: An EBMT Study on 151 Patients. (2007) (3)
Octogenarian newly diagnosed multiple myeloma patients without geriatric impairments: the role of age >80 in the IMWG frailty score (2021) (3)
Inhibition of Jak1/Jak2 Is More Effective Than Inhibition of Jak3 in Protecting Mice From Acute Graft-Versus-Host Disease (aGvHD) by Significantly Decreasing Alloreactive CD4+ T-Cells. (2012) (3)
Rituximab-Supplemented High-Dose Sequential Chemotherapy (HDS) Has Superior Response Rate and Event-Free Survival (EFS) Compared to R-CHOP in Poor Risk Follicular Lymphoma (FL) at Diagnosis: Results from a Multicenter Randomized GITMO Trial. (2005) (3)
Reduced-Intensity Conditioning Followed by Allogeneic Stem Cell Transplantation (allo-SCT) Is an Effective Salvage Treatment for Peripheral T-Cell Non-Hodgkin’s Lymphoma (PTCL). (2005) (3)
New drugs and allogeneic hematopoietic stem cell transplantation for hematological malignancies: do they have a role in bridging, consolidating or conditioning transplantation treatment? (2017) (3)
Sequential Therapy with IMID's in Relapsed-Refractory Multiple Myeloma Patients. (2009) (3)
Identification of Clonal Igh Gene Rearrangements By High-Throughput Sequencing of Cell Free DNA in Multiple Myeloma Patients (2015) (3)
Safety and clinical activity of the histone deacetylase inhibitor givinostat in combination with meclorethamine in relapsed/refractory Hodgkin lymphoma (HL). (2010) (3)
THE MUTATION OF N‐RAS ONCOGENE DOES NOT INVOLVE MYELOID AND ERYTHROID LINEAGES IN A CASE OF MULTIPLE MYELOMA (1993) (3)
Philadelphia-positive thrombocythemia with a complex translocation involving chromosomes 9, 15, and 22. (1989) (3)
Prospective, multicenter, randomized GITMO-IIL trial comparing intensive (R-HDS) to conventional chemoimmunotherapy (CHOP-R) in high-risk follicular lymphoma (FL) at diagnosis (2007) (3)
Development and Validation of a Simplified Score to Predict Early Relapse in Newly Diagnosed Multiple Myeloma in a Pooled Dataset of 2,190 Patients (2021) (3)
Donor Lymphocyte Infusions for the Treatment of Relapsed Non-Hodgkin Lymphoma Following Allogeneic Stem Cell Transplantation: A LWP-EBMT Study (2018) (3)
Alternative Donors (Umbilical Cord Blood and Haploidentical Donors) for Allogeneic Stem Cell Transplantation in Relapsed / Refractory Hodgkin Lymphoma: A Retrospective Analysis of the EBMT Lymphoma Working Party and the Spanish Group of Stem Cell Transplantation (GETH) (2015) (3)
Free calcium concentration in platelets of patients with essential hypertension. (1986) (3)
A PROSPECTIVE PHASE II STUDY ON TANDEM AUTOGRAFTING-ONMYELOABLATIVE ALLOGRAFTING FOR NEWLY DIAGNOSED MULTIPLE MYELOMA: FINAL RESULTS OF A MULTICENTER GITMO (GRUPPO ITALIANO TRAPIANTO MIDOLLO OSSEO) PROTOCOL (2007) (3)
P0655 : Lamivudine prophylaxis prevents hepatitis B reactivation in HBsAg-negative/anti-HBc-positive patients undergoing Rituximab-based chemotherapy for non-Hodgkin's B cell lymphoma (2015) (3)
Phase Ib study of avadomide (CC‐122) in combination with rituximab in patients with relapsed/refractory diffuse large B‐cell lymphoma and follicular lymphoma (2022) (3)
Relapse Is Uncommon in Patients with Large B-Cell Lymphoma Who Are in Complete Remission at the End of Fixed-Course Glofitamab Treatment (2022) (3)
WEEKLY CARFILZOMIB, CYCLOPHOSPHAMIDE AND DEXAMETHASONE (WKCYD) FOLLOWED BY MAINTENANCE WITH WEEKLY CARFILZOMIB (WK) IN ELDERLY PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM) (2016) (3)
Brief Chemoimmunotherapy Rituximab, Bendamustine, Mitoxantrone (R-BM) Followed by Rituximab Consolidation in Elderly Patients with Untreated Advanced Stage Follicular Lymphoma (FL): Preliminary Results of a Prospective Phase II Study by Fondazione Italiana Linfomi (FIL). (2012) (3)
CD8-Depleted Donor Lymphocyte Infusions Can Boost Immune Reconstitution after Haploidentical Stem Cell Transplantation Following Reduced-Intensity Conditioning Regimen. (2006) (3)
Rituximab (R) Maintenance Versus Observation After Short Term Chemoimmunotherapy R-FND as First Line Treatment in Elderly Patients with Advanced Follicular Lymphoma (FL): Updated Results and Safety of the Maintenance of An Intergruppo Italiano Linfomi (IIL) Randomized Trial. (2009) (3)
Molecular methods for detection of minimal residual disease following transplantation in lymphoid and plasma cell disorders. (2014) (3)
Myeloablative Versus Reduced Intensity Allogeneic Stem Cell Transplantation in Relapsed Hodgkin’s Lymphoma in Recent Years. a Retrospective Analysis of the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation (2014) (3)
Real-World Data of Nivolumab in Classical Hodgkin Lymphoma: Results from the Italian Expanded Access Programme (2017) (3)
Current state of art for transplantation paradigms in peripheral T-cell lymphomas (2013) (3)
Neutralizing monoclonal antibodies in haematological patients paucisymptomatic for COVID‐19: The GIMEMA EMATO‐0321 study (2022) (3)
Long-Term Follow-Up of High-Dose Chemotherapy Followed by Autologous Stem Cell Transplantation in Peripheral T-Cell Lymphomas at Diagnosis. (2004) (3)
S180: RG6234, A NOVEL GPRC5D T-CELL ENGAGING BISPECIFIC ANTIBODY, INDUCES RAPID RESPONSES IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: PRELIMINARY RESULTS FROM A FIRST-IN-HUMAN TRIAL (2022) (3)
The EBMT Lymphoma Working Party-European Mantle Cell Lymphoma Network Consensus Project On The Role Of Autologous and Allogeneic Stem Cell Transplantation In Mantle Cell Lymphoma: Recommendations Applying The Delphi Procedure (2013) (2)
Results of a Prospective Study Comparing Whole-Body Diffusion-Weighted Magnetic Resonance Imaging with Skeletal X-Ray and Magnetic Resonance of the Spine for Assessing Bone Disease in Multiple Myeloma. (2012) (2)
Randomized Trial of Busulfan with Cyclophosphamide Versus Busulfan with Fludarabine As Preparative Regimen to Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Acute Myeloid Leukemia: A Study from the Gruppo Italiano Trapianto Midollo Osseo (GITMO) (2014) (2)
Daratumumab, Bortezomib and Dexamethasone (DVd) vs Bortezomib and Dexamethasone (Vd) in RRMM Based on Prior Lines and Treatment Exposure: CASTOR (2017) (2)
Long-Term Follow-Up of the Randomized GITMO/IIL Trial Comparing CHOP-Rituximab vs. High-Dose Therapy with Rituximab (R-HDS) in High Risk Follicular Lymphoma (Fl): Updated Results Suggest the Use of R-HDS as Salvage Treatment. (2007) (2)
Bone marrow mammaglobin expression as a marker of graft-versus-tumor effect after reduced-intensity allografting for advanced breast cancer (2006) (2)
The Bbv Regimen: A Phase II Study with Bendamustine Plus Brentuximab Vedotin in Hodgkin Lymphoma and CD30+ Peripheral T-Cell Lymphoma in First Salvage Setting (2017) (2)
S1622 TANDEM AUTOLOGOUS-REDUCED INTENSITY ALLOGENEIC STEM CELL TRANSPLANTATION IN HIGH-RISK RELAPSED HODGKIN LYMPHOMA: A RETROSPECTIVE STUDY OF THE LWP-EBMT (2019) (2)
Upfront intensive chemo-immunotherapy with autograft in 199 adult mantle cell lymphoma patients: prolonged survival and cure potentiality at long term (2021) (2)
Nodal aggressive non-Hodgkin’s lymphoma in the adult: a review article (2005) (2)
High Frequency of Molecular Remissions (m-CR) in Multiple Myeloma Patients Achieving a Hematologic Complete Remission (CR) on Total Therapy II (TT-2). (2004) (2)
S220: GLOFITAMAB INDUCES DURABLE COMPLETE REMISSIONS AND HAS FAVORABLE SAFETY IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA AND ≥2 PRIOR THERAPIES: PIVOTAL PHASE II EXPANSION RESULTS (2022) (2)
The STRATUS trial (MM-010): A single-arm phase 3b study of pomalidomide plus low-dose dexamethasone (POM + LoDEX) in refractory or relapsed and refractory multiple myeloma. (2014) (2)
[Incidence and prediction of coronary heart disease in the Italian cohorts of the Seven Countries Study. 10 year experience (author's transl)]. (1980) (2)
CC-122 DLBCL-001: Phase Ib Study of CC-122 Plus Rituximab in Patients with Chemo-Refractory Diffuse Large B-Cell Lymphoma (DLBCL) (2017) (2)
Ixazomib-based induction regimens plus ixazomib maintenance in transplant-ineligible, newly diagnosed multiple myeloma: the phase II, multi-arm, randomized UNITO-EMN10 trial (2021) (2)
Reduced-Intensity Conditioning (RIC) Followed by Allogeneic Stem Cell Transplantation (SCT) for Relapsed Lymphomas: Impact of Pre-Transplantation Factors on Long-Term Outcome. (2005) (2)
Romidepsin-CHOEP followed by high-dose chemotherapy and stem-cell transplantation in untreated Peripheral T-Cell Lymphoma: results of the PTCL13 phase Ib/II study (2023) (2)
Sequential Approach with Bortezomib as Induction Before Autologous Transplantation, Followed by Lenalidomide as Consolidation-Maintenance in Untreated Multiple Myeloma Patients. (2009) (2)
Synergistic Anti-Tumor Efficacy of BET Inhibitors JQ1 and Otx-015 in Combination with Dasatinib in Preclinical Models of T-Cell Lymphomas (2016) (2)
CAR T-cells: Driving in the Fast Lane (2019) (2)
[The role of infective intestinal complications on the course of Crohn's disease and ulcerative rectocolitis]. (1993) (2)
Carfilzomib, bendamustine, and dexamethasone in patients with advanced multiple myeloma: The EMN09 phase 1/2 study of the European Myeloma Network (2021) (2)
Contributo dell'esame color Doppler-Doppler pulsato nella valutazione delle arterie renali in pazienti affetti da ipertensione arteriosa: esperienza preliminare Contribution of color and spectral Doppler studies in evaluating the renal arteries of patients suffering from arterial hypertension: A pre (2004) (2)
Unmanipulated Haploidentical Allogeneic Hematopoietic Cell Transplantation for Multiple Myeloma Using Post Transplant Cyclophosphamide Anti-Gvhd Prophylaxis (2016) (2)
Bendamustine in Combination with Gemcitabine and Vinorelbine (BEGEV) Is an Effective Regimen for Heavily Pretreated, Relapsed/Refractory Hodgkin Lymphoma Patients: A Multicenter, Retrospective Real-World Study (2018) (2)
Outcomes for Older Patients in Stratus (MM-010), a Single-Arm, and Phase 3b Study of Pomalidomide + Low-Dose Dexamethasone in Refractory or Relapsed and Refractory Multiple Myeloma (2014) (2)
Intensified Chemo-Immunotherapy Including up-Front Autologous or Allogeneic Stem Cell Transplantation (SCT) for Young Patients with Newly Diagnosed Peripheral T-Cell Lymphomas: Final Results of a Phase II Multicenter Prospective Clinical Trial (2012) (2)
Phase Ib study of combinations of avadomide (CC‐122), CC‐223, CC‐292, and rituximab in patients with relapsed/refractory diffuse large B‐cell lymphoma (2022) (2)
Secondary infections worsen the outcome of COVID‐19 in patients with hematological malignancies: A report from the ITA‐HEMA‐COV (2022) (2)
THE STRATUS (MM-010) TRIAL: A SINGLE-ARM, PHASE 3B STUDY EVALUATING SAFETY AND EFFICACY OF POMALIDOMIDE plus LOW-DOSE DEXAMETHASONE IN PATIENTS WITH REFRACTORY OR RELAPSED AND REFRACTORY MULTIPLE MYELOMA (2015) (2)
Gene Expression Profiling of CD34+/Lin- Cells of Patients with Chronic Myeloid Leukemia at Diagnosis and after 12 Months of Nilotinib (2014) (2)
Coronavirus Disease 2019 in Recipient of Allogeneic Hematopoietic Stem Cell Transplantation: Life-threating Features Within the Early Post-engraftment Phase (2020) (2)
High-Dose Rituximab In The Conditioning Regimen Before Allogeneic Stem Cell Transplantation Decreases Deaths Related To Gvhd Without Affecting The Anti-Lymphoma Effect (2013) (2)
Successful second autologous engraftment after long duration storage of hematopoietic stem cells (2013) (2)
COVID-19 Infection in Vaccinated Adult Patients with Hematological Malignancies. Preliminary Results from Epicovideha (Epidemiology of COVID-19 infection in patients with hematological malignancies: A European Haematology Association Survey) (2021) (2)
COVID-19 and hairy-cell leukemia: an EPICOVIDEHA survey (2022) (2)
Phase II Study of the Fondazione Italiana Linfomi on Gemcitabine Plus Romidepsin (GEMRO Regimen) in Relapsed and Refractory Peripheral T-Cell Lymphoma Patients (2015) (2)
A POOLED ANALYSIS OF THE IMPACT OF AGE ON OUTCOMES IN PATIENTS WITH REFRACTORY OR RELAPSED AND REFRACTORY MULTIPLE MYELOMA TREATED WITH POMALIDOMIDE plus LOW-DOSE DEXAMETHASONE (2016) (2)
Chemoimmunotherapy With R-chop Or High Dose Sequential Therapy (r-hds) With Autologous Stem Cell Transplantation (asct) For High Risk Dlbcl Patients: Preliminary Results Of The Randomized Rhds0305 Trial By Gruppo Italiano Terapie Innovative Nei Linfomi (gitil): 120 (2013) (2)
Peripheral T-Cell Lymphomas Not Otherwise Specified: Potential Novel Molecular Entities Based on Both Tumor and Microenvironment Cellular Components (2016) (2)
Phosphorylation Levels of Extracellular-Signal Regulated Kinase (ERK) and AKT in Circulating Lymphocytes Predict Response to Targeted Therapy with Kinase Inhibitors in Refractory/Relapsed Hodgkin Lymphoma Patients, (2011) (2)
In Vitro Purging in Autologous Stem Cell Transplantation for Chronic Lymphocytic Leukaemia. A Retrospective Analysis on Behalf of the Chronic Leukaemia Working Party of the EBMT. (2004) (2)
Long‐term molecular remission with lenalidomide treatment of relapsed chronic lymphocytic leukemia (2013) (2)
Safety and Efficacy of Idelalisib Treatment of Chronic Lymphocytic Leukemia (CLL) or Lymphoma Relapsing after Allogeneic Hematopoietic Cell Transplantation (alloHCT): A Survey By the EBMT Chronic Malignancies and Lymphoma Working Parties (2017) (2)
Correlative Analyses of Cytokine Release Syndrome and Neurological Events in Tisagenlecleucel-Treated Relapsed/Refractory Diffuse Large B-Cell Lymphoma Patients (2019) (2)
A phase Ib, open-label, dose-escalation trial of the anti-CD37 monoclonal antibody, BI 836826, in combination with gemcitabine and oxaliplatin in patients with relapsed/refractory diffuse large B-cell lymphoma (2021) (2)
TARC before ASCT Is Highly Predictive of Outcome in Patients with Relapsed or Refractory (R/R) Classical Hodgkin Lymphoma (cHL) after First-Line Therapy (2016) (2)
Lack of efficacy of convalescent plasma in COVID‐19 patients with concomitant hematological malignancies: An Italian retrospective study (2022) (2)
Rituximab, Bendamustine and Cytarabine Followed By Venetoclax (V-RBAC) in High-Risk Elderly Patients with Mantle Cell Lymphoma (2021) (2)
CD8-Depleted Donor Lymphocyte Infusions Can Improve Both T- and B-Cell Reconstitution after Allogeneic Stem Cell Transplantation from Haploidentical Family Donors (2008) (2)
Molecular methods used for the detection of autologous graft contamination in lymphoid disorders. (2007) (1)
GATA-3 Expression in Peripheral T-Cell Lymphomas (PTCL): Identification of a Cut-Off and Prognostic Value in PTCL-NOS Versus Others Hystotypes (2015) (1)
The Genomic and Transcriptomic Landscape of Double-Refractory Multiple Myeloma (2019) (1)
EDAPA Project: Final Data of a Prevention Experience in Arezzo Territory (2005) (1)
Allogeneic Bone Marrow Transplantation From Unrelated Donors in Multiple Myeloma: A Study from the Italian Bone Marrow Transplantation Donor Registry (2011) (1)
OAB-004: Carfilzomib-based induction/consolidation with or without autologous transplant and Lenalidomide (R) or Carfilzomib-Lenalidomide (KR) maintenance: efficacy in high-risk patients of the FORTE study (2021) (1)
Prognostic Significance of Molecular Remission Determined by Highly Specific PCR after Dose-Reduced Allogeneic Stem Cell Transplantation (SCT) in Patients with Multiple Myeloma. (2004) (1)
A Phase 1b, Multi-Center, Open-Label Study of Novel Combinations of CC-122, CC-223, CC-292, and Rituximab in Diffuse Large B-Cell Lymphoma: CC-122-DLBCL-001 (2016) (1)
New drugs and allogeneic hematopoietic cell transplantation for hematological malignancies: potential roles as bridge to transplant, as consolidation or as part of the conditioning (2017) (1)
Treated Multiple Myeloma Patients: Demographic Characteristics, Incidence Rate and Mortality in Lombardy during the 2003-2009 Period (2014) (1)
Imatinib as Salvage Therapy for Patients with Refractory cGVHD: the Interim Analysis of the Prospective GITMO* Multicenter Study*Gruppo Italiano Trapianto Di Midollo Osseo. (2009) (1)
Ixazomib-Based Induction Followed By Single-Agent Ixazomib Maintenance in Transplant Ineligible, Newly Diagnosed Multiple Myeloma Patients: Updated Results of the EMN10-Unito Trial (2020) (1)
The EDAPA Project (Education of self-measurement of blood pressure) in Grottaglie (2013) (1)
P697: PONATINIB IN A REAL-LIFE SETTING: A RETROSPECTIVE ANALYSIS FROM THE MONITORING REGISTRIES OF THE ITALIAN MEDICINES AGENCY (AIFA) (2022) (1)
Efficacy of Autologous Stem Cell Transplantation in First Complete Remission in Patients with Peripheral T-Cell Lymphoma: A Multicenter Geltamo/FIL Study (2017) (1)
Identification of a Chromatin-Splicing Mutational Signature to Define Secondary Acute Myeloid Leukemia: A Report from the Northern Italy Leukemia Group (NILG) Prospective Trial 02/06 (2019) (1)
Weekly Carfilzomib in combination with cyclophosphamide and dexamethasone (wCCyd) in patients (pts) with newly diagnosed Multiple Myeloma (NDMM): a phase 1/2 study of the European Myeloma Network Trialist Group (2015) (1)
Brentuximab Vedotin (BV) an Effective Treatment for Autologous (ASCT) and/or Allogeneic (alloSCT) Transplant naïve Patients with Relapsed/Refractory (R/R) Hodgkin Lymphoma (HL) : A retrospective Single-Institution Study (2014) (1)
Checkpoint Inhibition before Axicabtagene Ciloleucel Cell Therapy in Primary Mediastinal B-Cell Lymphoma (PMBCL) Treated in Real Life Setting (2020) (1)
Role of Allogeneic Stem Cell Transplantation (AlloSCT) in Patients Affected By Peripheral T-Cell Lymphomas (PTCL): No Difference in Outcome Between Patients Allografted at Diagnosis and in First Chemosensitive Relapse (2014) (1)
IN ADULT ACUTE MYELOID LEUKAEMIA (AML) ALL RISK SUBSETS BENEFIT FROM A SEQUENTIAL HIGH-DOSE PROGRAMME AS EARLY RESCUE OF FIRST INDUCTION FAILURE: A REPORT FROM NORTHERN ITALY LEUKAEMIA GROUP (NILG) (2010) (1)
Incidence of Secondary Myelodysplastic Syndrome/Acute Leukemia in 1,266 Lymphoma Patients Following High-Dose Therapy and Autograft: A Study from GITIL (Gruppo Italiano Terapie Innovative nei Linfomi). (2006) (1)
Revealing Transcriptome Deregulation upon Genomic Complexity in Multiple Myeloma (2020) (1)
OUTCOMES FOR OLDER PATIENTS WITH REFRACTORY OR RELAPSED AND REFRACTORY MULTIPLE MYELOMA TREATED WITH POMALIDOMIDE plus LOW-DOSE DEXAMETHASONE IN THE STRATUS (MM-010) TRIAL, A SINGLE-ARM, PHASE 3B STUDY (2015) (1)
Epidemiological study of inflammatory bowel diseases in BRA, Piemonte, Italy: Methodological problems (2001) (1)
Iberdomide (CC-220) Monotherapy or in Combination with an Anti-CD20 Monoclonal Antibody As Effective Therapy in Patients with Relapsed/Refractory Lymphoma: Early Results from a Phase 1/2 Study (2022) (1)
Long-term safety for patients with tisagenlecleucel-treated relapsed/refractory diffuse large B-cell lymphoma (2022) (1)
Allografting for patients with advanced hematological malignancies: non-myeloablative conditioning followed by the reinfusion of lymphocytes engineered with hsv thymidine kinase gene (2000) (1)
High-dose chemotherapy followed by autologous transplantation may overcome the poor prognosis of diffuse large B-cell lymphoma patients with MYC/BCL2 co-expression (2016) (1)
STRATUS(TM) (MM 010): A Single Arm, Phase 3b Study Evaluating Safety and Efficacy of Pomalidomide (POM) + Low Dose Dexamethasone (LoDEX) in Patients (Pts) With Refractory or Relapsed and Refractory Multiple Myeloma (RRMM) (2015) (1)
DONOR LYMPHOCYTE INFUSIONS INDUCE DURABLE RESPONSES IN PATIENTS WITH FOLLICULAR, MANTLE AND T CELL LYMPHOMAS RELAPSING AFTER AN ALLOSCT. AN EBMT‐LWP STUDY (2019) (1)
EXPRESSION OF MET MRNA AS PROGNOSTIC MARKER IN MULTIPLE MYELOMA PATIENTS TREATED WITH NOVEL DRUGS (2010) (1)
POLATUZUMAB VEDOTIN + OBINUTUZUMAB + VENETOCLAX IN PATIENTS WITH RELAPSED/REFRACTORY (R/R) FOLLICULAR LYMPHOMA (FL): PRIMARY ANALYSIS OF A PHASE 1B/2 TRIAL (2021) (1)
Efficacy and Safety of Parsaclisib in Patients with Relapsed or Refractory Marginal Zone Lymphoma: Primary Analysis from a Phase 2 Study (CITADEL-204) (2021) (1)
Allogeneic transplantation for peripheral and cutaneous T-cell lymphomas (2009) (1)
RG6234, a GPRC5DxCD3 T-Cell Engaging Bispecific Antibody, Is Highly Active in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Updated Intravenous (IV) and First Subcutaneous (SC) Results from a Phase I Dose-Escalation Study (2022) (1)
[The prediction of coronary heart disease. A mathimatical model applied to Italian field studies (author's transl)]. (1975) (1)
Effect of Age and Previous Autologous Transplant on Treatment-Related Mortality and GVHD in 140 Patients Treated with Reduce-Intensity Conditioning and Allograft for Advanced Hematological Malignancies. (2004) (1)
Brentuximab Vedotin As Single Agent in the Treatment of Relapsed/Refractory CD30 Positive Peripheral T-Cell Lymphoma Patients: A Phase 2 Study of the Fondazione Italiana Linfomi (2020) (1)
Carfilzomib, Pomalidomide, and Dexamethasone As Second-line Therapy for Lenalidomide-refractory Multiple Myeloma (2022) (1)
Rituximab with Dose-Adjusted EPOCH (R-DA-EPOCH) with or without Autologous Stem Cell Transplantation (ASCT) As First Line Treatment in Patients with Aggressive B-Cell Lymphoma with MYC and BCL-2 and/or BCL-6 Gene Rearrangements or Increase Copy Number (2020) (1)
Molecular Remission Can Be Attained in Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) and Follicular Lymphomas after Reduced Intensity Conditioning (RIC) and Allogeneic Stem Cell Transplantation (ALLO-SCT). (2004) (1)
Patients Outcome after Chimeric Antigen Receptor (CAR) T-Cells Failure in Aggressive B-Cell Lymphomas: Role of Immunotherapy and Prognostic Factors (2022) (1)
Unrelated Donor Hematopoietic Cell Transplantation after Non-Myeloablative Conditioning for Patients with High Risk Multiple Myeloma. (2006) (1)
Prognostic factors for survival in renal cell cancer patients undergoing allogeneic stem cell transplantation: A report from the EBMT Solid Tumours Working Party. (2004) (1)
A Case-Matched Analysis Comparing Lenalidomide After Autologous or After Allogeneic Stem Cell Transplantation Demonstrates a Survival Advantage in Allografted Myeloma Patients (2012) (1)
An Integrated Analysis of Cardio-Vascular Adverse Events of Carfilzomib, Cyclophosphamide and Dexamethasone in Elderly Newly Diagnosed Myeloma Patients Enrolled in 3 Phase I/II Trials (2016) (1)
Clinical Impact of an Accurate Genetic Characterization of Older Acute Myeloid Leukemia Patients: A Report from the Northern Italy Leukemia Group (NILG) Randomized Trial 02/06 (2018) (1)
Tandem transplant with autografting followed by non-myeloablative allografting for treatment of multiple myeloma: an Italian multi center trial (2003) (1)
FIRST REPORT OF THE REAL‐LIFE PROSPECTIVE OBSERVATIONAL STUDY “CAR‐T CELL IN DIFFUSE LARGE B‐CELL AND PRIMARY MEDIASTINAL LYMPHOMAS” OF THE ITALIAN SOCIETY OF HEMATOLOGY (2021) (1)
Chapter 85 – T-Cell Lymphomas (2017) (1)
Brief Chemoimmunotherapy Rituximab (R)-FND ± R Maintenance as First Line Treatment in Elderly Patients with Advanced Follicular Lymphoma (FL): Preliminary Analysis of a Prospective Randomized IIL Trial (2008) (1)
A 41-Gene Signature Predicts Complete Response (CR) to Bortezomib-Thalidomide-Dexamethasone (VTD) As Induction Therapy Prior to Autologous Stem-Cell Transplantation (ASCT) in Multiple Myeloma (MM) (2011) (1)
The Hematopoietic Cell Transplantation-Specific Comorbidity Index (HCT-CI) Predicts Survival and Non-Relapse Mortality in Lymphoma and Myeloma Patients Undergoing Reduced-Intensity or Non-Myeloablative Allogeneic Stem Cell Transplantations . (2008) (1)
Salvage treatment with pomalidomide-cyclophosphamide prednisone produces similar outcomes as compared to prior therapies in patients with relapsed/refractory multiple myeloma (2013) (1)
Continuous treatment improves survival of newly diagnosed multiple myeloma patients achieving complete response: data from 5 phase III trials including young and elderly patients (2015) (1)
A Model for the Prediction of Expected Effectiveness of a Treatment Using Experimental Data from an On-Going Preventive Trial on CHD (1979) (1)
Current role of allogeneic stem cell transplantation in follicular lymphoma. (2007) (1)
Italian Real Life Experience with Brentuximab Vedotin: Results of a National Observational Study on Relapsed/Refractory Anaplastic Large Cell Lymphoma (2016) (1)
Whole Genome Sequencing of Unique Paired SMM/MGUS Progressing to MM Samples Reveals a Genomic Landscape with Diverse Evolutionary Pattern (2016) (1)
Hyperchidam Verona897 Regimen Is Effective in Treatment of Advanced Peripheral T Cell Lymphoma (PTCL): The GITIL Experience in 33 Cases. (2007) (1)
A Prospective Phase II Study on Tandem Autografting-Nonmyeloablative Allografting for Newly Diagnosed Myeloma: Final Results of the Gruppo Italiano Trapianto Midollo Osseo. (2007) (1)
The Real Life Accessibility to CAR T-Cell Therapy: Current Experience in the Only Active Center in Italy (2019) (1)
P010 Incidence and risk factors of secondary myelodysplastic syndrome/acute leukemia occurrence following peripheral blood progenitor cell autograft: a GITIL (Gruppo Italiano Terapie Innovative Nei Linfomi) survey on 1266 lymphoma patients (2007) (1)
Selective inhibitors of nuclear export in aggressive B-cell lymphomas. (2020) (1)
Clinical and molecular remission following reduced intensity conditioning and allogeneic transplantation in a patient with refractory multiple myeloma. (2002) (1)
INO-CD22: A Multi-Center, Real-Life Study on Inotuzumab-Ozogamicin Safety and Effectiveness in Adult Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia (2021) (1)
9200 ORAL A Phase 3 Study Comparing Melphalan-Prednisone-Lenalidomide (MPR) With High-dose Melphalan and Autologous Transplantation (MEL200) in Newly Diagnosed Patients With Multiple Myeloma (MM) (2011) (1)
Abstract 1693: The combination of romidepsin and bendamustin is synergistically cytotoxic and reverses the malignant phenotype in preclinical models of T-cell lymphoma (2014) (1)
Peripheral blood or bone marrow cells myeloablative conditioning allogeneic transplantation for multiple myeloma (2007) (1)
On-Demand Plerixafor with Cyclophosphamide and G-CSF for Hematopoietic Stem-Cell Mobilization in Multiple Myeloma Patients: Preliminary Results of a Prospective Observational Study (MOZOBL06877) (2020) (1)
Allogeneic Stem Cell Transplantation (Allo-SCT) Following a Reduced-Intensity Conditioning (RIC) Regimen in Relapsed Peripheral T-Cell Lymphomas (PTCL): Results at 4 Year of Median Follow-up. (2009) (1)
Dexamethasone, Cytarabine and Cisplatin or Oxaliplatin Schedule (DHAP or Ox-DHA) Is Effective and Widely Applicable in Chronic Lymphocytic Leukemia and Waldenström Macroglobulinemia. (2009) (1)
Addition of Rituximab in Reduced Intensity Conditioning Regimens for B-Cell Malignancies Does Not Influence Transplant Outcomes: EBMT Registry Analyses Following Allogeneic Stem Cell Transplantation for B-Cell Malignancies (2021) (1)
SARS-CoV-2 Interstitial Pneumonia Treated With Tocilizumab in a Patient Affected by Classical Hodgkin Lymphoma (2020) (1)
AUTOLOGOUS STEM CELL TRANSPLANTATION AS PART OF FIRST‐LINE THERAPY IN PATIENTS WITH PERIPHERAL T‐CELL LYMPHOMA: A MULTICENTER GELTAMO/FIL STUDY (2019) (1)
MULTI‐OMICS LANDSCAPE OF SPLENIC MARGINAL ZONE LYMPHOMA (SMZL) ‐ INTERIM ANALYSIS OF IELSG46 STUDY (2019) (1)
Bortezomib versus lenalidomide in multiple myeloma patients at first relapse: first interim analysis of a phase III study (2015) (1)
Prolonged Survival of Lymphoma Patients Achieving Complete Remission Following High-Dose Sequential Chemotherapy and Autograft (HDS Program): A GITIL (Gruppo Italiano Terapie Innovative Nei Linfomi) Retrospective Study on 1,266 Patients. (2006) (0)
Safety and activity of the multikinase inhibitor sorafenib in heavily pretreated patients with refractory/relapsed malignant lymphomas: Final results of a phase II study. (2011) (0)
A284 Cytarabine-Based Regimens for Mobilization of Peripheral Blood Stem Cells in Multiple Myeloma (2009) (0)
High-Dose Rituximab in the Conditioning Regimen Before Allogeneic Stem Cell Transplantation Reduces the Incidence of Acute Gvhd in B-Cell Lymphomas (2011) (0)
Long-term molecular remission after conventional chemotherapy in a patient with Philadelphia-negative acute lymphoblastic leukemia. (1996) (0)
HEMATOLOGY AND ALLOGENEIC BONE MARROW TRANSPLANTATION (ETMO) (2011) (0)
Rituximab Dose Adjusted EPOCH Improves Progression-Free Survival of Patients Affected By Diffuse Large Cell Lymphomas with Double Expression of MYC and BCL2 Proteins (2017) (0)
Outcome of Hodgkin's Lymphoma Patients After Reduced-Intensity Allogeneic Stem Cell Transplantation: Complete Remission Status Has the Most Relevant Clinical Impact along with Extranodal Disease and C-Reactive Protein Before Transplant (2010) (0)
Effect of Age on Outcomes With Pomalidomide (POM) + Low-Dose Dexamethasone (LoDEX) in Patients (Pts) With Refractory or Relapsed and Refractory Multiple Myeloma (RRMM) in the STRATUSTM Trial (MM-010), A Single-Arm, Phase 3b Study (2015) (0)
Safety and Efficacy of Subcutaneous Rituximab in Previously Untreated Patients with CD20+ Diffuse Large B-Cell Lymphoma or Follicular Lymphoma: Results from an Italian Phase IIIb Study (2022) (0)
Analysis of the genomic and transcriptomic landscape of chemoresistant multiple myeloma (2019) (0)
Therapy, Pharmacoeconomics and Pharmacovigilance (2007) (0)
Abstract 3123: Peripheral T cell lymphoma-associated fibroblasts promote tumor growth in anin vivomodel (2018) (0)
SARS‐CoV‐2 infection and vaccination in patients with hairy‐cell leukaemia (2022) (0)
Alkylator-Based Conditioning for Allogeneic Hematopoietic Stem Cell Transplantation (alloHSCT) in Lymphoma: A Registry Study Comparing Thiotepa-, Busulfan-, Melphalan- and Treosulfan-Containing Regimens On Behalf of the EBMT Lymphoma Working Party (2012) (0)
Challenges for the next decade: allogeneic stem cell transplantation in chronic lymphocytic leukemia. (2012) (0)
Brentuximab vedotin in the treatment of relapsed/refractory CD30+ peripheral T‐cell lymphoma: A FIL phase 2 study (2022) (0)
SAFETY AND EFFICACY OF BORTEZOMIB IN RELAPSED MULTIPLE MYELOMA FOLLOWING REDUCED INTENSITY/NONMYELOABLATIVE CONDITIONINGS AND ALLOGENEIC HAEMATOPOIETIC CELL TRANSPLANTATION (2006) (0)
Tisagenlecleucel and Axicabtagene Ciloleucel Expansion Kinetics and CAR T Cell Attributes in the Infusion Products Are Early Predictors of Clinical Efficacy (2021) (0)
Role of Reduced-Intensity Conditioning Followed by Allogeneic Stem Cell Transplantation In Patients with Multiple Myeloma Relapsing After Autograft: a Donor Versus No Donor Analysis (2010) (0)
Long-Term Outcome of Therapy-Related Myelodysplastic Syndromes and Acute Myeloid Leukemias Arising in Patients Treated for Lymphoma or Solid Tumors. (2007) (0)
P1174: THE COMBINATION OF QUALITATIVE AND QUANTITATIVE METABOLIC PARAMETERS PREDICTS PROGRESSION-FREE SURVIVAL IN PATIENTS WITH LARGE B-CELL LYMPHOMAS (LBCL) TREATED WITH ANTI-CD19 CAR-T CELLS. (2022) (0)
B094 Melphalan, Prednisone and Lenalidomide: Kinetics of Hematologic Toxicity and Time to Event Results (2009) (0)
TANDEM AUTO-MINI ALLO APPROACH FOR NEWLY DIAGONSED MULTIPLE MYELOMA: AN UPDATE OF THE ITALIAN EXPERIENCE (2005) (0)
The long-term outcome of high-risk follicular lymphoma patients receiving intensive therapy with autograft as primary treatment: Results from three consecutive prospective trials performed in Italy over the past 18 years (2009) (0)
A442 Role of Comorbidities in Multiple Myeloma Patients Receiving RIC Allograft (2009) (0)
marrow-derived Graft Composition and Myeloablative Haploidentical Transplant with Post-transplant Cyclophosphamide: Cd4+ T Cell Count Strongly Influences Survival Outcomes : p072 (2016) (0)
Effect of Dioxin (TCDD) on Gene Transcription of Human CD34+ Hematopoietic Cells. (2007) (0)
Allogeneic Stem‐cell Transplantation (2021) (0)
NEXT GENERATION SEQUENCING (NGS) CONFIRMED THE ADVERSE CLINICAL IMPACT OF RUNX1 MUTATIONS IN A SUBSET OF ACUTE MYELOID LEUKEMIA NORMAL KARYOTYPE PATIENTS NEGATIVE FOR RISK DEFINING GENES MUTATIONS AND HOMOGENOUSLY TREATED WITHIN A CLINICAL TRIAL (NILG AML 02/06) (2017) (0)
Integration of Transcriptional and Mutational Data improves the Stratification of 1 Peripheral T-Cell Lymphoma 2 (2019) (0)
CD3+ Graft Cell Count Predicts Chronic Gvhd Incidence in Haploidentical Allogeneic Transplantation Using Post-Transplant Cyclophosphamide (2018) (0)
Adverse event (AE) management in patients (pts) with relapsed and refractory multiple myeloma (RRMM) taking pomalidomide (POM) plus low dose-dexamethasone (LoDEX): A pooled analysis from 3 clinical trials. (2016) (0)
Brentuximab Vedotin for relapsed Hodgkin lymphoma after allogeneic hematopoietic cell transplantation: a report from the EBMT Lymphoma Working Party (2020) (0)
Molecular a nd C linical R emissions i n M ultiple M yeloma: Role o f A utologous a nd A llogeneic T ransplantation of H ematopoietic C ells (1999) (0)
Adverse Event (AE) Management With Pomalidomide (POM) + Low-Dose Dexamethasone (LoDEX) in the STRATUS(TM) Trial: A Phase 3b Study Evaluating Safety and Efficacy in Patients (Pts) With Refractory or Relapsed and Refractory Multiple Myeloma (RRMM) (2015) (0)
Subject Index, Vol. 6 (Suppl. 1), 1986 (1986) (0)
UPDATED RESULTS OF THE FIL “MIRO” STUDY, A MULTICENTER PHASE II TRIAL COMBINING LOCAL RADIOTHERAPY AND MRD‐DRIVEN IMMUNOTHERAPY IN EARLY‐STAGE FOLLICULAR LYMPHOMA (2021) (0)
Safety and Efficacy of Pomalidomide Plus Low-Dose Dexamethasone (POM + LoDEX) in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM) in Italy: A Subanalysis of the Stratus Trial (MM-010) (2015) (0)
Role of Cell Source and Graft Composition in Haploidentical Transplantation Using Post-Transplant Cyclophosphamide (2016) (0)
Myc Expression and Tumor-Infiltrating T Cells Are Associated with Response in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma Treated with Tisagenlecleucel in the Juliet Trial (2021) (0)
Noninvasive Prediction of Acute Graft-Verus-Host Disease Following Allogeneic Hematopoietic Stem Cell Transplantation by Circulating miRNA Profiling (2011) (0)
Allogeneic Stem Cell Transplantation in Patients with Therapy-Related Acute Myeloid Leukemia and Myelodysplastic Syndromes: Effect of Patient Characteristics and Treatment History. (2010) (0)
breast cancer and donor lymphocyte infusions for patients with metastatic renal and Nonmyeloablative conditioning followed by hematopoietic cell allografting (2013) (0)
Long-term results of the phase III GITMO/FIL trial of CHOP-R versus R-HDS plus autograft in high-risk follicular lymphoma (FL) at diagnosis. (2014) (0)
PF227 PROGNOSTIC VALUE OF CLONAL HEMATOPOIESIS-MUTATIONS DETECTED AT DIAGNOSIS IN ACUTE MYELOID LEUKEMIA PATIENTS WITH NORMAL KARYOTYPE (2019) (0)
Primary Plasma Cells Expressing CD52 Are Efficiently Targeted In Vivo by Alemtuzumab. (2004) (0)
Hevylite and Freelite Tests in Newly Diagnosed Multiple Myeloma: Clinical Utility and Correlations with Clinical Features (2016) (0)
An uncommon cause of weaning failure from mechanical ventilation (2015) (0)
Second malignancies and cardiovascular diseases in long‐term Hodgkin lymphoma survivors: The Istituto Nazionale Tumori of Milan (INT) experience (2017) (0)
Ciclo XXVII IDENTIFICATION AND VALIDATION OF CRITICAL 1 Q 21 “ ACHILLES HEEL ” VULNERABILITES OF MULTIPLE MYELOMA (2016) (0)
availability transplantation : a retrospective study based on the time of HLA typing survival of Hodgkin lymphoma patients relapsing after autologous Allogeneic transplantation improves the overall and progression-free (2010) (0)
Prognostic Relevance of Neutrophil to Lymphocyte Ratio (NLR) and Lymphocyte to Monocyte Ratio (LMR) in Newly Diagnosed Advanced-Stage Hodgkin Lymphoma Patients Treated up-Front with a PET-2 Risk Adapted Protocol (2018) (0)
The role of autotrasplantation in chronic lymphocytic leucemia and results from the italian group. (2002) (0)
Analysis of Patient (Pt) Outcomes By Prior Treatment and Depth of Response in Stratus (MM-010), a Phase 3b Study of Pomalidomide + Low-Dose Dexamethasone (POM + LoDEX) in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM) (2015) (0)
[H2 antagonists and the heart]. (1986) (0)
Abstract 2207: A 41-gene signature predicts complete response (CR) to Bortezomib-Thalidomide-Dexamethasone (VTD) as induction therapy prior to autologous stem-cell transplantation (ASCT) in multiple myeloma (MM). (2013) (0)
Multicenter Phase II Study on Haploidentical Bone Marrow Transplantation Using a Reduced-Intensity Conditioning Regimen and Posttransplantation Cyclophosphamide in Patients with Poor-Prognosis Lymphomas. (2021) (0)
Rituximab for indolent lymphomas before and after allogeneic hematopoietic stem cell transplantation (2015) (0)
Developments in Other Haematological Malignancies: Other Lymphoid Malignancies (2022) (0)
A063 Reduced-Intensity Conditioning Allogeneic Stem Cell Transplantation in Myeloma: A Prospective Trial (2009) (0)
P932: ON-DEMAND PLERIXAFOR WITH CYCLOPHOSPHAMIDE AND G-CSF FOR HEMATOPOIETIC STEM-CELL MOBILIZATION IN MULTIPLE MYELOMA PATIENTS: FINAL RESULTS OF THE MOZOBL06877 STUDY (2022) (0)
Francesco Lo Coco, a distinguished hematologist and a friend (2019) (0)
dyscrasias Mutational activation of N- and K-ras oncogenes in plasma cell (2011) (0)
infusions contribute to improve T-cell recovery malignancies: posttransplantation CD8-depleted donor lymphocyte conditioning regimen for the treatment of advanced hematologic Haploidentical stem cell transplantation after a reduced-intensity (2013) (0)
A274 Long-Term Outcome After Allogeneic Hematopoietic Stem Cell Transplantation in Multiple Myeloma (2009) (0)
Allogeneic Stem Cell Transplantation in Hodgkin Lymphoma: The Timing of Relapse after Autologous Transplant and Primary Refractory Disease Do Not Impact the Survival Outcomes (2015) (0)
Carfilzomib, bendamustine, dexamethasone in patients with advanced multiple myeloma: The EMN09 Phase I/II study of the European Myeloma Network (2019) (0)
S244: EFFECT OF ANTI-SPIKE NEUTRALIZING MONOCLONAL ANTIBODIES ON COVID-19 PROGRESSION AND TIME TO VIRAL CLEARANCE IN PATIENTS WITH HEMATOLOGICAL MALIGNANCIES AND SARS-COV-2 INFECTION: THE GIMEMA EXPERIENCE (2022) (0)
Eosinophilic globules in bronchoalveolar lavage fluid of patients with systemic sclerosis-related interstitial lung disease: a diagnostically useful, previously unreported finding in a retrospective and prospective study, including differential diagnosis with other idiopathic and secondary interstit (2008) (0)
ALLOGENEIC STEM CELL TRANSPLANTATION FOLLOWING A REDUCED INTENSITY CONDITIONING REGIMEN IN RELAPSED PERIPHERAL T-CELL LYMPHOMAS (PTCL): RESULTS AFTER A MEDIAN FOLLOW-UP OF 67 MONTHS (2011) (0)
A097 PAD-MEL100-LP-L in Elderly Untreated Myeloma Patients (2009) (0)
Genetic lesions in chronic lymphocytic leukemia: what's ready for prime time use? (2010) (0)
The chronological order of copy number changes in hyperdiploid multiple myeloma patients (2018) (0)
Met Over-Expression Is a Prognostic Factor for Myeloma Patients Treated with Novel Agents (2009) (0)
ONE-HUNDRED-EIGHT CONSECUTIVE NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS TREATED WITH THE TANDEM AUTO-TBI BASED MINI-ALLO APPROCH (2006) (0)
High Cure Rates of the Short-Term GITIL Chemotherapy Programme for Adult Patients with Burkitt Lymphoma (2014) (0)
PCR-based diagnostics for minimal residual disease monitoring (2009) (0)
Improved Immune Reconstitution Following Pre-Emptive CD8-Depleted Donor Lymphocyte Infusions (DLIs) after Haploidentical Stem Cell Transplantation (SCT) Using a Reduced-Intensity Conditioning (RIC) Regimen. (2005) (0)
Effectiveness and management of ponatinib as second-line treatment in chronic myeloid leukemia: an analysis from the monitoring registries of the Italian medicines agency (AIFA) (2023) (0)
Prognostic factors for survival in renal cell cancer patients undergoing allogeneic stem cell transplantation: A report from the EBMT Solid Tumours Working Party (2004) (0)
THE SEE AND TREAT FOR THE MANAGEMENT OF ASYMPTOMATIC PRESSURE INCREASE: PP.14.25 (2010) (0)
A refined composite clinical score for the early identification of the predicted Poor Mobilizers (PM): a GITMO analysis. (2015) (0)
Validation of the Cibmtr Score in Predicting the Outcome of Hematopoietic Stem-Cell Transplantation in AML Patients Not in Complete Remission At the Time of Conditioning: A Retrospective Analysis On Behalf of the Gruppo Italiano Trapianto Di Midollo Osseo (GITMO) (2012) (0)
FIL‐PTCL13: PHASE IB/II STUDY OF ROMIDEPSIN/CHOEP FOLLOWED BY HIGH‐DOSE CHEMOTHERAPY AND TRANSPLANTATION IN UNTREATED PERIPHERAL T‐CELL LYMPHOMAS. (2017) (0)
AUTOGRAFTING FOLLOWED BY LOW DOSE TBI BASED NON MYELOABLATIVE ALLOGRAFTING IN MULTIPLE MYELOMA: THE GITMO EXPERIENCE (2003) (0)
allogeneic HSCT in first chronic phase allogeneic HSCT not in first chronic phase autologous HSCT in first chronic phase autologous HSCT not in first chronic phase (2006) (0)
Oncogenes in the Pathogenesis of Multiple Myeloma (1996) (0)
MOLECULAR PROLIFE BY NEXT GENERATION SEQUENCING OF ACUTE MYELOID LEUKEMIA WITH NORMAL KARYOTYPE: CLINICAL RESULTS FROM THE PROSPECTIVE TRIAL 02/06 OF THE NORTHERN ITALY LEUKEMIA GROUP (NILG) (2018) (0)
Prevalence of Ocular Disorders in Multiple Myeloma (2017) (0)
Decisional Role of Interim PET in Relapsed/Refractory Classical Hodgkin Lymphoma Treated with Begev Chemotherapy As First Salvage (2022) (0)
Pre-emptive CD8-depleted donor lymphocyte infusions to overcome long-lasting immune deficiency after haploidentical stem cell transplantation with a reduced intensity conditioning regimen (2006) (0)
Rituximab with Dose-Adjusted EPOCH (R-DA-EPOCH) As First-Line Treatment in Patients with Double-Hit Lymphoma: Preliminary Results in 35 Consecutive Patients from Two Institutions (2017) (0)
Nilotinib For Steroid-Refractory Chronic Graft Versus Host Disease (SR-cGVHD): Preliminary Results Of a Phase I-II GITMO Study (Gruppo Italiano Trapianto di Midollo Osseo) (2013) (0)
Genomic patterns of progression in smoldering multiple myeloma (2018) (0)
P004: Advanced stage classical Hodgkin lymphoma (cHL) patients with a positive interim-PET (PET-2) Deauville score (DS) 5 after 2 ABVD cycles: A pooled analysis of individual patient data of three multicenter trials (2022) (0)
Allogeneic Stem Cell Transplantation (Allo-SCT) after Treatment with Programmed Cell Death-1 (PD-1) Checkpoint Inhibitors for Relapsed/Refractory Classic Hodgkin Lymphoma (R/R cHL) Is Associated with an Unprecedented Low Relapse Rate (2018) (0)
Neutrophils and other myeloid cells (PP-034) (2010) (0)
Analysis of Circulating Microrna Expression Profile In Patients Transplanted From Matched Unrelated Donors (MUD) Identifies mir203 as a Putative Marker of aGVHD (2010) (0)
Hypertension and atherosclerosis: causality or causelessness? (2013) (0)
TANDEM AUTOGRAFTING-NONMYELOABLATIVE ALLOGRAFTING FOR NEWLY DIAGNOSED MULTIPLE MYELOMA: THE GITMO EXPERIENCE (2007) (0)
Prevalence of inflammatory bowel diseases in BRA, Piemonte, Italy (2001) (0)
S221: BORTEZOMIB TO R-DHAP COMPARED TO R-DHAP IN RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA ELIGIBLE TO STEM CELL TRANPLANTATION: FINAL RESULTS OF PHASE II RANDOMIZED FIL-VERAL12 (2022) (0)
ROMIDEPSIN‐CHOEP PLUS UP‐FRONT STEM‐CELL TRANSPLANTATION IN PERIPHERAL T‐CELL LYMPHOMA (PTCL): FIRST ANALYSIS OF THE PHASE II FIL‐PTCL13 STUDY (2021) (0)
Physicians Abstracts (2015) (0)
Highly Prolonged Overall Survival Following Reduced Intensity Allogeneic Stem Cell Transplantation for Multiple Myeloma in the New Drugs Era (2015) (0)
PF591 EFFICACY AND SAFETY OF DARATUMUMAB, LENALIDOMIDE, AND DEXAMETHASONE (D-RD) IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM): UPDATED SUBGROUP ANALYSIS OF POLLUX BASED ON CYTOGENETIC RISK (2019) (0)
Long Term Follow-Up of a Donor Versus no Donor Comparison in Multiple Myeloma Patients at First Relapse After Previous Autotransplant (2015) (0)
Interferon γ Enhances the Anti-Myeloma Activity of the Fully Human Anti-HLA-DR Monoclonal Antibody 1D09C3. (2006) (0)
Italian Real Life Experience with Brentuximab Vedotin: Results of a National Observational Study on Relapsed/Refractory Hodgkin's Lymphoma (2016) (0)
In Vivo Jak1/Jak2 Inhibition Protects From Acute GvHD While Maintaining Robust Anti-Tumor Activity (2013) (0)
P114: Very late relapses in patients with Hodgkin Lymphoma occuring ≥5 years after initial treament with chemotherapy ± radiotherapy: Treatment strategies and prognostic factors for the outcome (2022) (0)
BRENTUXIMAB VEDOTIN FOR RELAPSED HODGKIN LYMPHOMA AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION: a RETROSPECTIVE STUDY OF THE EBMT LYMPHOMA WORKING PARTY (2017) (0)
9.1 Education for Self-Measurement of Blood Pressure as an Instrument for the Management of Hypertensive Patients and Promoter of Appropriate Medication (2007) (0)
A Novel Method for Molecular Enumeration of Circulating Tisa-Cel and Axi-Cel in Lymphoma Patients (2020) (0)
Reduced-intensity allogeneic stem cell transplantation is an effective salvage treatment for relapsed aggressive non-Hodgkin’s lymphoma (2009) (0)
patients receiving imatinib for steroid-refractory chronic GVHD Long-term outcome and prospective validation of NIH response criteria (2013) (0)
Reduced intensity allogeneic stem cell transplantation is an effective salvage treatment for relapsed non-Hodgkin’s and Hodgkin’s lymphomas (2006) (0)
P158 Long-term outcome of therapy-related myelodysplastic syndromes and acute myeloid leukemias arising in patients treated for lymphoma or breast cancer (2007) (0)
Coordinatore: Chiar.mo Prof. Paolo Corradini BIOLOGICAL AND CLINICAL RELEVANCE OF MIRNA EXPRESSION SIGNATURES IN PRIMARY PLASMA CELL LEUKEMIA Relatore: Chiar.mo Prof. Antonino NERI (2013) (0)
Intravenous and Subcutaneous Administration of RG6234, a Novel GPRC5DxCD3 T-Cell Engaging Bispecific Antibody, Is Highly Active in Patients with Relapsed/Refractory Multiple Myeloma (RRMM): Biomarker Results from a Phase I Study (2022) (0)
A426 Bortezomib or Lenalidomide to Treat Disease Relapse After Allogeneic Transplantation in Myeloma (2009) (0)
Long-Term Analysis of an Open-Label, Multicentre, Randomized Phase 3 Trial Comparing Busulfan Plus Cyclophosphamide Versus Busulfan Plus Fludarabine As a Preparative Regimen for Allogeneic Stem-Cell Transplantation in Patients with Acute Myeloid Leukemia (2022) (0)
Direct Healthcare Costs of Treated Multiple Myeloma: Results from a Population-Based Study (2014) (0)
A 7-Gene Signature in Unmanipulated Leukaphereses Correlates with in-Vivo CAR T-Cell Expansion and Survival of Lymphoma Patients Receiving Tisagenlecleucel or Axicabtagene Ciloleucel Therapy (2022) (0)
Efficacy and Safety of Ixazomib-Dexamethasone, Ixazomib-Cyclophosphamide-Dexamethasone, Ixazomib-Thalidomide-Dexamethasone and Ixazomib-Bendamustine-Dexamethasone for Elderly Newly Diagnosed Multiple Myeloma (NDMM) Patients: Analysis of the Phase II Randomized Unito-EMN10 Study (2019) (0)
Non-Restrictive Diet Does Not Increase Infections in Patients with Neutropenia after Stem Cell Transplantation: Final Analysis of the Neutrodiet Multicenter, Randomized Trial (2022) (0)
Long-Term Outcome of High-Dose Sequential Chemotherapy with Autografting (i-HDS) in Follicular Lymphoma at Diagnosis: An Update of the Prospective Multicenter Consecutive Trial of the "Gruppo Italiano Trapianto Di Midollo Osseo" (Gitmo). (2004) (0)
Timing the initiation of multiple myeloma (2020) (0)
High Response Rate with Favorable Survival Projections in High-Risk Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Receiving R-CHOP-14 or Early Intensified Chemotherapy with Rituximab and Autograft (R-HDS): Results of the Interim Analysis of A GITIL Prospective Multicenter Phase III Study. (2009) (0)
Risk of Early Severe Infections in Newly Diagnosed Multiple Myeloma Patients Treated with Novel Agents: A Pooled Analysis (2020) (0)
Outcomes of Patients (Pts) With Refractory or Relapsed and Refractory Multiple Myeloma (RRMM) and Renal Impairment (RI) Treated With Pomalidomide (POM) + Low-Dose Dexamethasone (LoDEX) in the Phase 3b STRATUS(TM) Trial (MM-010) (2015) (0)
Lenalidomide Plus Dexamethasone Versus Lenalidomide Plus Melphalan and Prednisone: A Case-Control Study in Newly Diagnosed Elderly Myeloma Patients. (2009) (0)
Outcome of Soft-Tissue Plasmocytomas in Newly Diagnosed Multiple Myeloma Patients Treated with New Drugs (2018) (0)
Analysis of mutations and structural variants to redefine the genomic landscape of multiple myeloma and its clinical implications (2018) (0)
REAL LIFE EXPERIENCE WITH BRENTUXIMAB VEDOTIN: THE ITALIAN STUDY ON 234 RELAPSED/REFRACTORY HODGKIN'S LYMPHOMA (2017) (0)
A Multicenter Phase I/II EMN Study of Carfilzomib in Combination with Bendamustine and Dexamethasone (CBd) in Relapsed and/or Refractory Patients with Multiple Myeloma (2017) (0)
PHASE II FIL‐PTCL13 STUDY OF ROMIDEPSIN‐CHOEP FOLLOWED BY HIGH‐DOSE CHEMOTHERAPY AND TRANSPLANTATION IN UNTREATED PERIPHERAL T‐CELL LYMPHOMAS (2019) (0)
The Therapeutic Effect of Lenalidomide Is Enhanced After Allogeneic Stem Cell Transplantation: Results of a Case-Control Study (2011) (0)
LOW-DOSE TBI-BASED NON-MYELOABLATIVE ALLOGRAFTING IN NEWLY DIAGNOSED MULTIPLE MYELOMA (2004) (0)
PF602 OUTCOME OF EXTRA-MEDULLARY DISEASE IN NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS TREATED WITH NEW DRUGS (2019) (0)
The Addition of Romidepsin to CHOEP and High-Dose Chemotherapy Plus Stem Cell Transplantation Did Not Ameliorate the Outcome of Untreated Angioimmunoblastic T-Cell or Follicular T-Helper Lymphoma: Subgroup Analysis of Phase II FIL-PTCL13 Study (2022) (0)
Long-term results of reduced-intensity conditioning followed by allogeneic transplantation in relapsed lymphomas (2009) (0)
Reduced-intensity allogeneic stem cell transplantation using related haploidentical donors for relapsed or refractory lymphomas : evidence of anti-tumour activity in poor prognosis disease (2008) (0)
Microarray of Bone Marrow CD34+/Lin- Cells from Patients with Chronic Myeloid Leukemia (CML) (2014) (0)
Allografting from unrelated donors in multiple myeloma: a study by the Italian bone marrow donor registry (2012) (0)
Met mRNA value predicts outcome in multiple myeloma patients (2010) (0)
The Genomic Landscape of Multiple Myeloma Complex Structural Variations (2017) (0)
Analysis of the genomic lanscape of multiple myeloma highlights novel candidate prognostic markers and disease subgroups (2017) (0)
Clinical aspects of hospitalised infants with bronchiolitis and helmet-CPAP non-invasive ventilation (2012-2013) (2014) (0)
Disease Monitoring in Multiple Myeloma Patients Using Liquid Biopsy and Next Generation Sequencing of IGH Gene Rearrangements (2016) (0)
Pharmacologic Inhibition of JAK1/JAK2 Signaling Protects from Acute GvHD While Preserving Gvt in Mice (2014) (0)
Long Term Response After Lenalidomide Treatment for Patients with Multiple Myeloma Relapsed After at Least Two Lines of Therapy. (2009) (0)
High Dose Chemotherapy with Autograft in First Relapse May Overcome the Poor Prognosis of Diffuse Large B-Cell Lymphoma Patients with MYC/BCL2 Co-Expression (2015) (0)
S241: NON-RESTRICTIVE DIET DOES NOT INCREASE GASTROINTESTINAL INFECTIONS AND FEBRILE NEUTROPENIA IN PATIENTS WITH NEUTROPENIA AFTER STEM CELL TRANSPLANTATION: DATA FROM A MULTICENTRE, RANDOMIZED TRIAL (2022) (0)
CART Therapy or Allogeneic Stem Cell Transplantation in ≥ Third Line Treatment of Large B Cell Lymphoma (LBCL) (2022) (0)
QUANTITATIVE METABOLIC PARAMETERS EVALUATION IN PATIENTS WITH AGGRESSIVE B‐CELL LYMPHOMAS TREATED WITH ANTI‐CD19 CAR T‐CELLS (2021) (0)
ALLOGENEIC TRANSPLANTATION IN HODGKIN'S LYMPHOMA AFTER A FAILED AUTOGRAFT: LONG TERM OUTCOMES AND GRAFT‐VERSUS‐HOST DISEASE FREE/RELAPSE‐FREE SURVIVAL (GRFS) (2017) (0)
a Novel Method for the Detection of Minimal Residual Disease in B-Cell Malignancies: Ion Semiconductor Sequencing for the Evaluation of Igh Gene Rearrangements (2014) (0)
Whole Genome Sequencing Reveals Recurrent Structural Driver Events in Peripheral T-Cell Lymphomas Not Otherwise Specified (2018) (0)
PS1313 FEASIBILITY AND PRELIMINARY RESULTS OF A PROSPECTIVE EVALUATION OF RESIDUAL DISEASE IN DIFFUSE LARGE B-CELL LYMPHOMAS USING DEEP SEQUENCING OF CELL FREE DNA AND DNA FROM FORMALIN FIXED BIOPSIES (2019) (0)
Targeting CD19 in diffuse large B‐cell lymphoma: An expert opinion paper (2022) (0)
Evaluation of MRD Status by Flow Cytometry and PCR in Multiple Myeloma Elderly Patients Receiving Autologous Stem Cell Transplantation After Bortezomib-Supplemented Mobilization and Conditioning (2012) (0)
Targeting the DNA Damage Response to Increase Anthracycline-Based Chemotherapy Cytotoxicity in T-Cell Lymphoma (2022) (0)
Qualitative and quantitative polymerase chain reaction monitoring of minimal residual disease in relapsed (2009) (0)
SARS‐CoV‐2 infection in patients with chronic lymphocytic leukemia: The Italian Hematology Alliance on COVID‐19 cohort (2022) (0)
Outcomes of Mismatched Related Allogeneic Stem Cell Transplantation for Chronic Lymphocytic Leukemia: A Retrospective Study on Behalf of the Chronic Malignancies Working Party of the EBMT (2016) (0)
Whole-body DWI, whole-body and whole-spine MRI in multiple myeloma (2010) (0)
AUTOGRAFTING FOLLOWED BY NON MYELOABLATIVE TBI-BASED ALLOGRATING FOR TREATMENT OF MULTIPLE MYELOMA: A MULTI-CENTER TRIAL (2002) (0)
Tandem autografting-nonmyeloablative allografting for newly diagnosed multiple myeloma: The GITMO (gruppo italiano trapianto midollo osseo) experience (2007) (0)
The Landscape of Structural Variant Signatures in Multiple Myeloma Identifies Distinct Disease Subgroups with Implications for Pathogenesis (2018) (0)
Does the addition of thalidomide to MP or low-intensity SCT improve survival in elderly multiple myeloma patients? (2008) (0)
Qualitative and Quantitative PCR Monitoring of MRD: Practical Implications of a Surrogate Marker for GVL Effect after RIC Allogeneic Transplantation in Relapsed Chronic Lymphocytic Leukemia. (2007) (0)
Combination of Deauville score and quantitative positron emission tomography parameters as a predictive tool of anti‐CD19 chimeric antigen receptor T‐cell efficacy (2022) (0)
Prognostic factors and outcome of reduced-intensity conditioning followed by allogeneic stem cell transplantation in patients with multiple myeloma relapsed after autografting and rescued with new drugs (2011) (0)
Autologous and Allogeneic Stem Cell Transplantation for T-Cell Lymphomas (2013) (0)
ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION FOR PERIPHERAL T‐CELL LYMPHOMA: COMPARABLE OUTCOMES OF HAPLO‐IDENTICAL VS. MATCHED DONORS. A CIBMTR & EBMT ANALYSIS (2021) (0)
Donor Lymphocyte Infusions and Rituximab Are An Effective Treatment Strategy for B-Cell Lymphoma Relapsing After Reduced Intensity Allogeneic Stem Cell Transplantation. (2009) (0)
PCR-Detectable N onneoplastic B cl-2/IgH R earrangements A re Common i n N ormal S ubjects a nd C ancer P atients a t D iagnosis but R are i n S ubjects T reated W ith C hemotherapy (2003) (0)
FIRST SALVAGE TREATMENT WITH BENDAMUSTINE AND BRENTUXIMAB VEDOTIN IN HODGKIN LYMPHOMA: A PHASE 2 STUDY OF FIL ONLUS (2019) (0)
Safety Profile of Idelalisib in Patients with Refractory Follicular Lymphoma: Interim Analysis of a Noninterventional Study (2020) (0)
Decrease of Serum TARC Levels As Predictive Biomarkers of Response to Targeted Therapy with Kinase Inhibitors in Refractory/Relapsed Hodgkin Lymphoma Patients (2014) (0)
Impact of Minor Histocompatibility Antigens (mHAg) Mismatches On Gvhd Incidence in Non-Myeloablative or Reduced Intensity Allogeneic Stem Cell Transplantation. (2009) (0)
Randomized Trial Comparing R-chop-14 Versus High Dose Sequential Chemotherapy in High Risk Patients with Diffuse Large B-cell Lymphomas. Final results from the Gitil-rhds0305 study: O064 (2016) (0)
2.1 The Project of Education of Self Measurement of Blood Pressure in Grottaglie (2007) (0)
PF596 EFFICACY AND SAFETY OF DARATUMUMAB, BORTEZOMIB, AND DEXAMETHASONE (D-VD) IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM): UPDATED SUBGROUP ANALYSIS OF CASTOR BASED ON CYTOGENETIC RISK (2019) (0)
The Risk of Secondary Myelodysplastic Syndrome/Acute Leukemia Following Intensive Therapy and Autograft Correlates with the Type of Cells Grafted: A Survey on 1,347 Lymphoma Patients Receiving the High-Dose Sequential (HDS) Program. (2007) (0)
G-CSF Stem Cell Mobilization Is Protective Against Acute Graft-Versus-Host Disease (aGvHD) by Increasing Myeloid-Derived Suppressor Cell (MDSC) Frequencies (2012) (0)
Peripheral T‐cell lymphomas (2015) (0)
High Response Rates to Bortezomib-Dexamethasone Followed by Donor Lymphocyte Infusions in Patients with Multiple Myeloma Relapsing After Allogeneic Stem Cell Transplantation: Results of a Multicentric Prospective Phase II Study (2011) (0)
VERY LATE REALAPSES (VLR) ≥5 YEARS AFTER INITIAL TREATMENT WITH CHEMOTHERAPY±RADIOTHERAPY (CT±RT) IN HODGKIN LYMPHOMA (HL): A JOIN STUDY ON TREATMENT STRATEGIES AND PROGNOSTIC FACTORS FOR THE OUTCOME: PF472 (2019) (0)
Ipertensione e aterosclerosi: causalità o casualità? Hypertension and atherosclerosis: causality or causelessness? (2009) (0)
P1188: PERSONALIZED TREATMENT ACCORDING TO BIOLOGICAL PROFILE IMPROVES OUTCOME OF NEWLY DIAGNOSED PATIENTS AFFECTED BY DIFFUSE LARGE B-CELL LYMPHOMA: A REAL-LIFE EXPERIENCE (2022) (0)
Final Results of a Multicenter Prospective Phase II Trial of Allogeneic Transplantation for Relapsed/Refractory CD20+ B-Cell Lymphomas: Effect of Rituximab on Graft-Versus-Host Disease-Free/Relapse-Free Survival (GRFS) (2016) (0)
Significant Survival Improvement with Maintenance in Patients Achieving a Complete Response: Pooled Analysis of 4 Italian Phase III Trials in Newly Diagnosed Multiple Myeloma Patients (2015) (0)
Patients with aaIPI 2-3 Diffuse Large B-Cell Lymphoma Achieve 75% Long-Term Survival Following First-Line Rituximab-Supplemented High-Dose Sequential Chemotherapy and Autograft: Final Results of the Prospective Phase II GITIL (Gruppo Italiano Terapie Innovative nei Linfomi) Trial. (2007) (0)
7129 Long-term follow-up of metastatic renal cancer patients undergoing HLA-identical reduced-intensity allografting (2009) (0)
PS1216 CAR T-CELL THERAPY FOR LYMPHOMAS IN ITALY: THE ISTITUTO NAZIONALE DEI TUMORI OBSERVATIONAL STUDY AFTER THE EMA APPROVAL (2019) (0)
P105: Decisional role of interim PET in relapsed/refractory classical Hodgkin Lymphoma treated with four begev cycles (2022) (0)
Total Metabolic Tumor Volume Is Confirmed As Independent Prognostic Factor in Treatment Naïve Follicular Lymphoma Patients and Can be Combined with FLIPI2 to Improve Prognostic Accuracy. a FOLL12 Substudy By the Fondazione Italiana Linfomi (2022) (0)
Early Reduction of Serum TARC Levels Predicts Prognosis of Patients Treated with a PET-Adapted Strategy for Advanced Stage Hodgkin Lymphoma (HL) in the GITIL/FIL HD0607 Trial (2017) (0)
PF758 MULTI-CENTER, PHASE II STUDY ON HAPLOIDENTICAL BONE MARROW TRANSPLANTATION USING A RIC REGIMEN AND POST-TRANSPLANT CYCLOPHOSPHAMIDE IN PATIENTS WITH POOR PROGNOSIS LYMPHOMAS (2019) (0)
Original Maspin and mammaglobin genes are specific markers for RT-PCR detection of minimal residual disease in patients with breast cancer (2005) (0)
Telomere Length of Hematopoietic Cells Following Autologous and Allogeneic Stem Cell Transplant (SCT) Reflects That of Grafted Cells: Can the Transplant of Younger Stem Cells Be Exploited To Rejuvenate Hematopoiesis?. (2007) (0)
S173: T-CELL ACTIVATION AND MYELOMA CELL KILLING CONFIRM THE MODE OF ACTION OF RG6234, A NOVEL GPRC5D T-CELL ENGAGING BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (2022) (0)
P1144: RADIOIMMUNOTHERAPY (RIT) VERSUS AUTOLOGOUS HEMATOPOIETIC STEM-CELL TRANSPLANTATION (ASCT) IN RELAPSED/REFRACTORY (R/R) FOLLICULAR LYMPHOMA: A FONDAZIONE ITALIANA LINFOMI (FIL) PHASE III TRIAL. (2022) (0)
[Study of abdominal adipose tissue distribution using CAT in android type obesity]. (1988) (0)
Heavy+Light Chain and Free Light Chain Assays at Baseline and During Follow-up in EMN02/HO95 Multiple Myeloma Clinical Trial (2017) (0)
Salvage brentuximab vedotin prior to allogeneic hematopoietic cell transplantation in classical hodgkin lymphoma does not impact survival but reduces the incidence of chronic GVHD: a retrospective study of the EBMT Lymphoma Working Party. (2017) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Paolo Corradini?

Paolo Corradini is affiliated with the following schools:

University of Milan
University of Parma
University of Verona
University of Padua
Humanitas University
University of Turin
Columbia University
University of Bologna

Paolo Corradini's Academic­Influence.com Rankings

Paolo Corradini's Degrees

Why Is Paolo Corradini Influential?

Paolo Corradini's Published Works

Published Works

What Schools Are Affiliated With Paolo Corradini?

Paolo Corradini's AcademicInfluence.com Rankings